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Presence of increased numbers of CD8+ T cells in the tumors correspond to 
better overall   survival in the patients. Variety of immuno-therapies have shown 
considerable efficacy in the clinic, however, a multitude of patients remain 
unresponsive. Most of these immunotherapies rely on effector T cell responses in 
the tumor. A major obstacle in the success of these immunotherapies is poor 
recruitment of CD8+ T cells into tumors despite intact effector responses in the 
periphery. Therefore understanding the mechanisms that regulate CTL infiltration 
into tumors becomes essential. Previous studies in our laboratory suggested an 
important role for BLT1 in immune surveillance against tumors by regulating CTL 




investigated the roles of leukotriene B4 (LTB4) receptor - BLT1; and CXCR3, the 
receptor for CXCL9, CXCL10 and CXCL11 in anti-tumor immunity using a 
syngeneic B16 melanoma tumor model. BLT1-/- mice and CXCR3-/- mice on a 
C57BL/6 background were used to examine the function of these receptors in 
tumor progression. Significant acceleration in tumor growth and reduced survival 
was observed in both BLT1-/- and CXCR3-/- mice as compared to the WT mice. 
Analysis of tumor infiltrating leukocytes revealed significant reduction of CD8+ T 
cells in the tumors of BLT1-/- and CXCR3-/- mice as compared to WT tumors; their 
frequencies being similar in the periphery (spleen and TdLN). Significant 
reduction of Granzyme-B and IFNγ transcripts were observed in tumors of 
knockout mice compared to WT mice.  
Adoptive transfer of tumor experienced WT but not BLT1-/- or CXCR3-/- CD8+ T 
cells reduced tumor growth significantly in Rag2-/- mice, which correlated with 
reduced infiltration of knockout CD8+ T cells into tumors. Co-transfer of WT CD8+ 
T cells with either of the knockout CD8+ T cells in tumor bearing Rag2-/- mice 
showed that WT CD8+ T cells did not facilitate additional knockout CD8+ T cell 
infiltration to tumors. BLT1/CXCR3 double deficient mice displayed similar tumor 
kinetics as single knockout mice and showed lack of synergism.  
The requirement for BLT1 and CXCR3 in inducing checkpoint blockade mediated 
anti-tumor response was tested. While anti-PD-1 based vaccine significantly 
attenuated tumor growth in WT mice, the vaccine completely lost its efficacy in 
BLT1-/-, CXCR3-/- or BLT1-/-CXCR3-/- mice that correlated with failure of knockout 




BLT1 and CXCR3 in CTL migration to tumors and thus can be targeted to 
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Emerging data clearly demonstrates that the immune system can curtail cancer 
progression, a concept termed “Immune-surveillance against tumors”. CD8+ T 
cells act as sentinels against tumors by directly eliminating the tumor cells. The 
prime focus of this research is to understand the mechanisms regulating CD8+ T 
cell migration to tumors with a particular emphasis on chemo-attractant 
receptors. The chapter begins with a brief description of the dual role of immune 
system in regulating as well as sculpting the tumor, a phenomenon known as 
immunoediting. The cellular and molecular mechanisms involved in killing tumor 
cells and how this knowledge is translated into various successful 
immunotherapies that have revolutionized the field of cancer therapies is 
described in greater detail with a particular focus on PD-1 blockade based 
therapies, Adoptive T cell therapies (ACT) and Chimeric Antigen Receptor (CAR) 
based therapies. Reasons behind failure of immunotherapies in cancer patients 
is discussed, defective CD8+ T cell infiltration to tumors being a major one as well 
as hurdles in achieving optimum CD8+ T cell infiltration to tumors.  
The importance of chemokines and their cognate receptors in regulating cancer 




outlined the background on Leukotriene B4 receptor BLT1; and CXCR3, receptor 





















Transformed cells arise due to genetic mutations resulting in uncontrolled cellular 
divisions. Tumor growth is a cumulative effect of three steps viz. initiation of a 
cancerous event in a cell, promotion of the cancerous event by proliferation and 
finally progression involving tumor growth and metastases [1]. Cancer 
development requires attainment of six hallmark capabilities: self-sufficiency in 
proliferation, insensitivity to anti-proliferative signals, evasion of apoptosis, 
unlimited replicative potential, the maintenance of vascularization and tissue 
invasion and metastasis [2].   
Multiple intrinsic and extrinsic mechanisms exist to prevent such aberrant cell 
divisions. These “intrinsic” cellular mechanisms protect the cells against various 
perturbed mutagenic insults or cell stresses including hypoxia, nutrient 
deprivation, DNA damage, tissue injury etc. Should the cell proliferation go 
beyond control, the cell activates apoptosis or cell death pathways through 
activation of pro-apoptotic machinery, engagement of death receptors, activation 
of tumor suppressor genes like p53, etc. If the transformed cells escape the 
intrinsic control, they are then subjected to the “extrinsic” mechanisms wherein 
neighboring cells sense the presence of a transformed cell and try to eliminate it. 
Dependency of cells on trophic environmental cell-cell contact signals or extra-
cellular matrix (ECM) dependence; genes controlling cellular junctions and 
polarity and finally detection and elimination of transformed cells by the immune 
system; constitute the three extrinsic mechanisms to prevent the maintenance of 




Dual role of immune system in tumor development 
The role of immune system in controlling cancer has long been a subject of 
debate. The initial clues for the involvement of immune system in cancer growth 
stemmed through the observation made by Virchow in 1863 that tumor biopsy 
samples contain leukocytes termed as “lymphoreticular infiltrate”. On the other 
hand, as far back as 1700s the observations that feverish infections in cancer 
patients occasionally led to cancer remissions suggested that immune activation 
and cancer remission might be associated. The very first attempt at using 
immunotherapies as cancer therapies was made by W. Coley in 1893 wherein he 
injected killed bacterial mixture of Streptococcus pyogenes and Serratia 
marcescens to cancer patients and observed tumor regression in some cases 
[4]. Since then several studies have later proven that immune system can curtail 
tumor growth as well as promote it.  
Inflammation promotion of cancers 
Recent studies have expanded the concept that inflammation plays a crucial role 
in tumor promotion. Only 10-15% of the cancers are hereditary and the rest are 
caused by somatic mutations at sites of infection, exposure to chemical irritant, 
cigarette smoke, environmental and dietary factors. The fact that patients 
suffering from inflammatory bowel disease or Crohn’s disease often develop 
colon cancers strongly correlates chronic inflammation with cancer development 
[5]. Patients positive for Hepatitis C infection and Helicobacter pylori infections 




associating infections to cancers [6, 7]. The use of Non-steroidal anti-
inflammatory drugs (NSAIDs) in the prevention of spontaneous tumors in Familial 
Adenomatous Polyposis (FAP) patients also establishes a strong connection 
between inflammation and cancer [8].  
Oncogenic event also occurs due to mutations caused by reactive oxygen 
species and nitrogen intermediates (ROS and RNI) as well as superoxide and 
hydroxyl radicals produced as a result of inflammation [9]. Studies on the role of 
NF-kB have provided further insights in the participation of inflammation in tumor 
growth. Murine model of colitis-associated cancer involves azoxymethane (AOM-
pre-carcinogen) mediated induction of an oncogenic event that by itself gives rise 
to fewer numbers of adenomas along the intestines. The adenomas can be 
augmented by simultaneous induction of colonic inflammation through repeated 
exposure to intestinal irritant dextran sulfate sodium (DSS). Inactivation of NF-kB 
pathway in colonic epithelial cells in an AOM-DSS model of intestinal 
tumorigenesis resulted in a significant reduction in the tumor incidence [10]. NF-
kB transcription factor was not only shown to be a key component of 
inflammation but also known to facilitate the survival of the initiated colonic 
epithelial cells. It was also involved in activating the myeloid immune cells to 
produce inflammatory cytokines like IL-1β, IL-6, TNFα, IL-12/IL-23; chemokines 
like KC, MIP-2, and inflammatory mediators like COX-2, STAT-3, MMP-9, etc. 
that promote the growth of cancerous cells. Ablation of NF-kB activity in pro-
tumorigenic tumor associated macrophages (TAMs) re-educated them to gain 




inflammation by secreting factors that allow the migration of various other 
inflammatory myeloid cells that promote the tumor growth. For example, COX-2 
is frequently expressed in tumor cells and is involved in the synthesis of 
prostaglandins and chemokines like IL-8, CCL2, CCL20, up-regulating the 
chemokine receptor CXCR4 that binds to the chemokine CXCL12 or SDF-1 
(stromal cell derived factor-1), activating matrix degrading enzymes, etc. [9]. 
Tumor suppressor genes are also involved in activating inflammatory pathways 
in tumor cells. For example, von Hippel-Lindau tumor suppressor protein (VHL) 
targets the transcription factor Hif-1α or hypoxia-inducible factor 1α for 
degradation. The role of HIF-1α in cellular response to hypoxia is very well 
established. Some of the functions of Hif-1α include initiating angiogenesis, 
interaction with NF-κB to promote TNFα production and is also known to help 
express CXCR4 chemokine receptor on tumor cells involved in metastasis [12].  
Immunesurveillance and Immunoediting of cancer 
Despite the semantics of correlation between inflammation and cancer, the 
immune system is still the third extrinsic mechanism to prevent tumorigenesis. In 
fact the pro-tumorigenic effects of immune system emerge if the cytotoxic 
immune cells do not eliminate the cancer cells. The notion that cancerous cells 
would emerge at an “incredible frequency” if the host defenses would not prevent 
the growth of continuously arising cancer cells was conceived in 1909 by Paul 
Erlich. Fifty years later Burnett and Thomas predicted that lymphocytes were 
responsible for eliminating the nascent tumor cells and hence introduced the 




unequivocal evidence reinforcing the beneficial role of the immune system in 
eliminating the tumor cells. By 1990s, the availability of better immunodeficient 
murine models on pure genetic background led to the importance of interferon 
gamma (IFNγ) and STAT1 (transcription factor required for IFNγ signaling) in 
rejection of transplanted tumors. This rekindled the role of lymphocytes in anti-
tumor immunity as demonstrated in spontaneously arising tumors as well as 
chemically induced tumors [13, 14]. The results obtained in immune-
compromised mice led to the paradox of tumor formation in immune-competent 
mice/individuals which led to the concept of “Cancer immunoediting” pioneered 
by Schreiber and colleagues that describes the dual roles of the immune system 
in three sequential steps of tumor progression namely Elimination, Equilibrium 
and Escape phases [13, 15].  
In the Elimination phase the innate (dendritic cells, macrophages, NK cells) and 
the adaptive immune cells (CD8+ and CD4+ T cells, γδ T cells) work in concert 
towards eliminating any nascent tumor cells. Release of effector cytokines like 
Type I (IFNα and IFNβ) and II (IFNγ) interferons, TNFα, IL-12 by the innate cells 
upon recognition of tumor antigens recruit the effector cells including effector 
CD8+ and CD4+ T cells as well as NK cells to the tumors. The CTLs themselves 
further express granzyme-B, perforin, TRAIL, Fas/FasL, IL-2, IFNγ, TNFα, 
NKG2D, IL-17 etc. that directly kill the tumor cells and enhance the antigenicity of 
tumor cells by enhancing the MHC-I expression on tumor cells [3, 16].  
In the Equilibrium phase, the tumor cells and immune cells exist in a state of 




elimination or escape. Effector cells (T cells) and cytokines (IFNγ, IL-12) are 
indispensable in this phase and there is a balance established between anti-
tumor and pro-tumor immune mechanisms [16, 17]. The immune cells can keep 
the tumors in a functionally dormant state, wherein tumor cells acquire genetic 
mutation because of the immune selective pressure leading to the generation of 
“tumor variants”. The tumor cell variants that emerge in the previous phase grow 
to become resistant to immune detection or elimination and become tolerized by 
establishing various immune-suppression mechanisms that allow the tumors to 
grow and become clinically detectable. 
The tumor now progresses to the next phase, Escape. The tumor-induced 
mechanisms include tumor cells acquiring additional somatic mutation, loss of 
response to IFNγ, loss of antigen presentation due to downregulation of MHC-I 
molecule on tumor cells, enabling infiltration of immune-suppressive cells as well 
as expression of immune-suppressive markers like PD-L1 on tumor cells. The 
immune induced mechanisms include subversion of T cell responses, T cell 
anergy, immune suppression via myeloid cells like TAMs, MDSCs (myeloid 
derived suppressor cells) as well as regulatory T cells (Treg) that express various 
immune suppressive factors like TGFβ, IL-10, IDO (indoleamine 2,3-
dioxygenase), FasL, galectin, VEGF, PD-1/PDL1, CTLA4 etc. [3, 16]. The 
amount of literature in understanding these three phases of immunoediting has 
been burgeoning in the past decade. The final outcome of tumor growth depends 





           
Figure 1:  The cancer immunoediting concept. Cancer immunoediting is an 
extrinsic tumor suppressor mechanism that engages only after cellular 
transformation has occurred and intrinsic tumor suppressor mechanisms have 
failed. In its most complex form, cancer immunoediting consists of three 
sequential phases: elimination, equilibrium, and escape. 





Patients with established cancers indicate the failure of immune surveillance 
mechanisms. The immune cells that are present in the tumors of these patients 
now actually promote the tumor growth by releasing pro-tumorigenic cytokines 
and chemokines. The conventional tumor therapies like radiotherapy and 
chemotherapies were originally aimed at killing the cancer cells directly; however, 
recent studies have demonstrated that these therapies are also immuno-
modulatory in nature. Given the beneficial role of immune surveillance in cancer, 
attempts are being made to jumpstart the anti-tumor responses. Therefore a 
major focus of the field of tumor immunology is to modulate the immune system 
such that the anti-tumor responses get activated and pro-tumorigenic responses 
get subverted.   
Cancer Treatment Approaches 
Surgery, radiotherapy and chemotherapy are the three most common standard of 
care treatment approached to most of the cancers. Most of the chemotherapy 
drugs as well as radiotherapy induce cancer killing by inducing apoptosis in 
cancer cells. While offering short term benefit, the standard of care treatments 
can lead to more aggressive cancer cells that become resistant to both 
chemotherapy and radiotherapy possibly due to disruption of intrinsic apoptosis 
machinery. One of the reasons behind the aggressiveness of cancer cells post 
therapy can be due to the negative effect of the radiation and chemotherapy on 
the immune system. It is now known that certain chemotherapy drugs that 
targeted cancer cells based on the rapid cell division criterion, also targeted the 




immunosuppression. Total body irradiation leads to ablation of patient’s immune 
system. Radiation was also shown to promote immunosuppressive mechanisms 
like activation of transforming growth factor-β and enhancing pro-tumorigenic 
function of macrophages. Also Treg cells are more resistant to radiation induced 
death compared to other T cells which leads to presence of more Treg compared 
to CTLs in the tumor.  
Recent studies have demonstrated that the standard of care therapies can have 
positive impact on immune system. Certain chemotherapy drugs and localized 
radiotherapy can induce immunogenic cell death, thus enhancing anti-tumor 
immunity [19, 20]. Local tumor irradiation instead of total body irradiation has 
recently shown to benefit the anti-tumor effect of the immune system. Even 
chemotherapies like cyclophosphamide and 5-fluorouracil are considered to be 
immune-modulatory in nature by eliminating suppressive Treg and MDSC 
immune cells thereby enhancing anti-tumor immunity. Hence radiotherapy and 
certain chemotherapy drugs can induce immunogenic cell death mechanisms 
that involve the activation of type-I IFNs that lead to activation of innate and 
adaptive system against tumors. Also, immunogenic cell death induces release 
of various tumor antigens/neo-antigens that act as endogenous vaccines [21-26]. 
This provides mechanistic rationale behind combining specific chemotherapies 
and/or radiation therapy with existing immunotherapies, thus opening up new 





Immunotherapy as cancer treatment strategy 
Immunotherapies have only recently emerged as a successful treatment modality 
for cancer [27-29]. Various studies indicated that adjuvants, lectins, IL-2 and 
interferons could target the tumor cells by activating the lymphocytes [30-32]. A 
series of landmark approvals by the FDA including a) IFNα2 for the adjuvant 
treatment of stage IIB/III melanoma in 1995, b) IL-2 for the treatment of 
metastatic melanoma and renal cell carcinoma in 1998, c) first ever cancer 
vaccine -  “Oncophage/vitespen” for treatment of renal cell carcinoma in Russia 
in 2008, d) approval of autologous Dendritic cell cancer vaccine (Provenge) for 
Stage IV hormone refractory prostate cancer and e) immune checkpoint 
blockade strategies such as anti-CTLA4 (Ipilimumab) in 2011 for melanoma, and 
anti-PD-1 (Pembrolizumab) in 2014 for advanced metastatic melanoma and non 
small cell lung carcinoma; have all been significant in reinforcing that 
immunotherapies hold tremendous potential to combat tumors thus starting a 
new wave of revolution in cancer therapeutics [33-39].  Three major lines of 
immunotherapy approaches emerged in recent years against tumors viz. a) 
employing Adoptive cell transfer therapy including chimeric antigen receptor 
therapy, b) blocking immune checkpoint inhibitory pathways like PD-1, CTLA, 
TIM3 and LAG3, and c) activating T cell co-stimulatory pathways by using 
agonistic antibodies to OX-40, 4-1BB, ICOS. These immune-therapies have 
higher success rates due to increased specificity to cancer antigens as well as 
inducing long lasting T cell responses and immunological memory. T cell based 




cell therapies including chimeric antigen receptor therapy, vaccine candidates 
like Prostvac targeting the prostate specific antigen (PSA) and various agonistic 
antibodies for co-stimulatory receptor candidates are currently in advanced 
clinical trials.  
An effective T cell dependent anti-tumor response involves five major steps: a) 
efficient antigen sampling by dendritic cells (DCs) and their maturation; b) 
migration of these DCs to tumor draining lymph nodes (TdLNs); c) 
recirculation/migration of naïve T cells to TdLNs; d) antigen presentation by the 
DCs to the T cells, clonal expansion and acquisition of effector functions in T 
cells and finally e) migration of these activated CTLs to tumors to execute their 
anti-tumor functions [40, 41]. Although all these steps are crucial and 
interconnected, the final outcome must be the presence of CD8+ T cells in tumors 
and with intact effector functions. Manipulating these steps of anti-tumor 
immunity has led to various successful immune-therapies against cancer. DC 
based vaccines, for example, accomplishes step 1 by enhancing the antigen 
loading and maturation ability of the DCs [34]. Immune checkpoint inhibitors i.e. 
anti-PD-1 and anti-CTLA4 antagonistic antibodies [39] and co-stimulatory agents 
(4-1BB, ICOS, GITR agonists, etc. [42]) as well as adjuvants (lectins, IL-2)  [43] 
when used accomplishes step 4 by enhancing the effector functions of the CD8+ 
T cells against tumor cells. Alternatively, immunotherapies like Adoptive T cell 
therapies (ACT) including Chimeric Antigen Receptor (CAR) therapy bypass all 




function [44]. The most successful immunotherapies relevant to the current 
project specifically in melanoma are detailed below.  
Immune checkpoint blockade: anti-PD-1 and anti-CTLA4 antibodies 
Inhibitory receptors present on the immune cells attenuate the immune 
responses to prevent excessive inflammation that can be detrimental to the 
tissues. T cell activation is a complex process and involves antigen specific 
stimulation via the TCR and a co-stimulatory signal. It is now increasingly clear 
that both co-stimulatory and co-inhibitory signals are required to maintain an 
effective T cell response. Enhancing signaling through co-stimulatory molecules 
(4-1BB, GITR, OX-40) and blocking the co-inhibitory molecules (CTLA4, PD-1, 
LAG3) can amplify T cell responses to tumors [45-47].  
CTLA4: CTLA4 is a type 1 transmembrane glycoprotein inhibitory receptor that is 
present on T cells and belongs to of the CD28/Immunoglobulin superfamily. By 
binding to B7-1 (CD80) and B7-2 (CD86) on APCs, CTLA4 competes with CD28 
costimulatory molecule to dampen T cell responses. Optimal crosslinking of 
CTLA4 with TCR-CD28 stimulation led to IL-2 suppression, proliferative arrest 
without induction of apoptosis. A monoclonal Ab was made by Allison and 
colleagues to specifically block CTLA4 in a preclinical model wherein significant 
anti-tumor immunity without any overt immune toxicity was achieved upon 
CTLA4 blockade [46]. Subsequently two fully humanized CTLA4 antagonistic 
antibody Ipilimumab and Tremilimumab were introduced in clinical trials in 2000 




overall response rates of 17% in patients with advanced melanoma with three 
year survival rates being 20% [48]. Subsequently, in 2010 Ipilimumab was the 
first immune-checkpoint blockade therapy that was FDA approved for metastatic 
melanoma [49].  
PD-1: PD-1 was originally identified in 1992 as a gene induced upon apoptotic 
cell death in a T cell hybridoma [50]. Later studies demonstrated that PD-1 
deficient mice showed signs of autoimmunity that suggested a role of PD-1 as an 
inhibitor of lymphocyte responses at peripheral tissues. Further insight on the 
role of PD-1 as an inhibitory receptor was gained from a chronic viral infection 
model [51, 52]. While expressed minimally on resting immune cells, PD-1 is 
broadly expressed on T cells, B cells, NK cells, DCs and macrophages upon 
activation.  PD-1 binds to its partners PD-L1 (B7-H1) and PD-L2 (B7-DC). PD-L1 
is broadly expressed on cells of both hematopoietic and non-hematopoietic 
lineage including tumor cells. PD-L1 expression is induced upon inflammatory 
cytokines like TNFα and interferons. PD-L2 expression is restricted to immune 
cells like DCs, macrophages and mast cells. CTLA4 and PD-1 control T cell 
responses by different mechanisms. They both block activation of Akt thereby 
blocking glucose uptake by CD28. However, PD-1 blocks PI-3K activation while 
CTLA4 blocks Akt downstream of PI3K. Adoptively transferred T cells express 
PD-1 and numerous tumor cells express PD-L1 suggesting the role of this 
signaling pathway in tumor immune evasion [53]. In 2014, Pembrolizumab was 
the first anti-PD-1 drug approved by the FDA against relapsed or refractory 




30% as compared to 16% by chemotherapy. Nivolumab was the second anti-PD-
1 drug to be FDA approved for metastatic melanoma and metastatic squamous 
non-small cell lung carcinoma (NSCLC). It showed 72% overall survival rate at 
one year for metastatic melanoma patients without BRAF mutation [48]. PD-1 
and CTLA4 combination blockade was shown to be more effective compared to 
either treatments alone [54]. Whole exome sequencing of non-small cell lung 
cancers treated with Pembrolizumab suggested that higher non-synonymous 
mutational landscape in lung tumors was associated with better objective 
response and clinical benefit [55]. The higher mutational burden also correlated 
with molecular smoking signature and increased neo-antigen burden [55]. This 
also explained why some patients were unresponsive to PD-1 blockade.  
Similarly, studies suggest that only a subset of CRC, may be a good 
candidate to PD-1 blockade therapy [56]. Microsatellite instable (MSI) subset of 
colorectal cancer comprises 15% of sporadic CRC and most familial CRC [57]. 
MSI, typically diagnosed by variable length DNA microsatellites, are mutations 
arising due to epigenetic silencing of DNA mismatch repair genes [58]. The high 
mutational burden in MSI tumors creates many tumor-specific neo-antigens 
compared to microsatellite stable tumors [59]. MSI positive tumors correspond to 
higher level of tumor-infiltrating leukocytes, T cell responses, PD-1 and PD-L1 
expression and hence better response to PD-1 blockade therapies [56, 57, 59]. 
  
Adoptive T cell therapy (ACT): This technology was pioneered by Dr. Steven 




vivo activated, stimulated and expanded autologous T cells with high affinity to 
tumor antigens back into the patients. Ex-vivo activation and culture of tumor 
specific T cells is possible outside of the endogenous host that has immune-
suppressive factors. Anti-tumor T cells with a CCR7+CD27+ CD28+ CD62L+ 
phenotype characteristic of central memory cells were more effective in ACT 
protocol than more differentiated effector cells [60]. Antigen specific cells are 
isolated from the freshly excised tumors and as soon as the anti-tumor activity is 
detected against specific antigens, cells were expanded in the presence of T cell 
stimulating antibody OKT3 and IL-2 (6000 IU/ml). Approximately 5×1010 cells 
were infused systemically following a non-myeloablative preparative regimen 
consisting of 60mg/kg cyclophosphamide for 2 days followed by 5 days 
of fludarabine at 25 mg/m2. IL2 was administered for 2–3 days at 7.2×105 IU/kg 
every 8 hr [61].  ACT today represents one of the most promising T cell based 
immunotherapy for melanoma, lymphoma and childhood leukemias. The source 
of the T cells could be PBMCs or tumor itself. The ACT procedure involves pre-
conditioning the patient by temporary ablation of immune system or 
lymphodepletion through total body irradiation or chemotherapy for removal of 
regulatory T cells, competition for homeostatic cytokines like IL-7 and IL-15 
involved in T cell survival and proliferation thereby enhancing the persistence of 
the transferred T cells [62]. The lymphodepletion regimen before ACT when 
combined with administering T cell growth factor IL-2 led to tumor eradication for 
prolonged durations [62-64]. Objective response rates for this therapy against 




complete tumor regression and disease free survival for more than 8 yrs [62]. 
Data from tumor exomic sequencing have enabled the identification and targeting 
of numerous non-synonymous mutations that result in new epitope generation 
[65]. ACT also includes TCR gene modified T cells against shared tumor 
differentiation antigens like MART-1, Carcinoembryonic antigen (CEA), cancer 
germ line antigens like NY-ESO-1, MAGE-A3 that have shown considerable 
success in various clinical trials [44]. Despite the success of ACT, a multitude of 
patients remain unresponsive. Upregulation of immune-suppressive molecules 
on the transferred CTLs (CTLA4 and PD-1), immune-suppressive tumor 
microenvironment (IDO, NOS-1), and the nature of tumor vasculature are some 
of the reasons behind differential response rates of ACT. Attempts are being 
made to utilize T cells with TCR against a specific antigen or patient specific 
tumor antigen called neo-antigens based on mutations in tumor DNA, identify T 
cell subsets to be used for ACT (Naïve, Tcm, Tscm, Tem), identify T cell growth 
factors used (IL-2, IL-7, IL-15) to enhance persistence, proliferation and survival 
of T cells, and understand better host preconditioning protocols for 
lymphodepletion and T cell engraftment [66-69]. Studies are now undertaken to 
understand specific markers to identify and sort out from the tumor immune 
infiltrate that would give better anti-tumor responses in an adoptive cell transfer 
setting. Recent studies showed that PD1+CD8+ T cells and not PD1-CD8+ T cells 
represent the cohort of clonally expanded tumor reactive TILs and included T 




Chimeric Antigen Receptor therapy: In line with ACT, Chimeric Antigen 
Receptor therapy (CAR) is another immunotherapy that has shown considerable 
success with hematological cancers. It involves genetic modification of T cells 
such that they stably express chimeric antibodies conferred with antigen 
specificity. Briefly, chimeric antigen receptor is a fusion of antigen recognition 
domain of an antibody with the intracellular domain of CD3zeta chain or FcγRI. 
These first generation CARs effectively demonstrated cytotoxicity and T cell 
activation but failed to show proliferation and survival of T cells upon continuous 
antigen exposure. Studies suggested that the first generation CARs become 
anergic in the absence of co-stimulation in the tumor mileu. Second and third 
generation CARs encompassed the combination of CD3zeta chains with co-
stimulatory molecules like CD28, CD27, 4-1BB and OX-40 [71, 72]. The antigen 
specificity and HLA independent recognition are some of the benefits of using 
CARs. Autologous T cells transduced to express CD19 CARs alongwith 4-1BB 
co-stimulatory molecule have shown considerable success with 50% of them 
achieving partial or complete remissions and T cells persisting beyond two years 
in patients with refractory and relapsed B cell chronic lymphocytic leukemia [73]. 
However, there can be various side effects like cytokine release syndrome and 
tumor lysis syndrome and B cell aplasia. Nonetheless, there is an increasing 






Reasons behind partial efficacy of immunotherapies 
The past decade has witnessed a major revolution in immunotherapy as a 
promising treatment modality for cancer. Despite the tremendous success of 
immunotherapies, large numbers of cancer patients still remain unresponsive. 
For example, PD-1 blockade therapy leads to tumor progression free survival in 
only 30% of the patients while ACT treatments lead to complete tumor regression 
in only 22% of the patients [48, 62]. The reason behind this is probably multifold. 
As indicated before the process of anti-tumor immunity requires proper execution 
of various steps and involvement of various cells. Any immunotherapy approach 
would have to overcome various hurdles. For example, “antigenicity” of the tumor 
is an important measure for potential susceptibility to immune therapies. Tumor 
can express variety of non-mutated or mutated antigens or even lose the 
antigenicity by reducing the antigen presentation via MHC-I downregulation or 
dysregulation in antigen presentation machinery. Although recent studies have 
demonstrated that immune response can be mounted against the neo-antigens 
or the antigens derived from somatic mutations that are specific to cancer cells 
(and not normal cells); the mutational landscape could be quite different across 
every individual that complicates the use of immunotherapies to the generalized 
population. Also the efficacy of immunotherapies to neo-antigens suggest the 
possibility that higher number of mutations correlate with enhanced response to 
immunotherapy [74]. Importantly, the failure of immunotherapies in some patients 
stems through the off-target toxic side-effects from the use of immunotherapies 




syndrome, cytokine storm syndrome are the various side-effects that limit the 
efficacy of the T cell based immunotherapies. 
Studies have revealed that some immunotherapies including cancer vaccines are 
able to mount anti-tumor responses in the periphery but not in the tumor. Tumor 
mileu being inherently tumor suppressive is a major obstacle in success of 
immunotherapies. Immunotherapies that boost T cell responses fail to maintain 
the anti-tumor responses in the tumor due to immune-suppressive cells, 
cytokines, growth factors, hypoxic environment, etc. that inactivate or subvert the 
T cell based responses [41].  
Another major impediment acknowledged only recently is defective CD8+ T cell 
infiltration to tumors despite effective responses in the periphery [40, 75]. Studies 
have demonstrated that less than 2% of adoptively transferred T cells actually 
reach the tumor [76, 77]. Majority of the transferred cells remain in the periphery 
or are found in lung and liver, which may also be a reason behind off-target 
responses and toxicities seen in T cell based therapies. Enhancing effector T cell 
recruitment to tumors by employing chemokine/chemokine receptor pathways is 
a crucial strategy to circumvent these issues. For an effective immune response 
to occur it is of importance that specific immune cells (anti-tumorigenic and not 
pro-tumorigenic) be recruited at specific locations (tumors versus the periphery). 
A major focus of this thesis is to understand how chemoattractant receptors 
regulate the efficacy of immunotherapies. Indeed studies conducted herein 
suggest that absence of BLT1 and CXCR3 chemoattractant receptors completely 




indispensable role for both BLT1 and CXCR3 in achieving optimum efficacy of 
PD-1 blockade based immunotherapy. 
Chemoattractants and leukocyte migration 
Leukocyte migration involving both homeostatic recirculation among lymphoid 
organs and migration to inflamed sites including tumors is orchestrated and 
tightly regulated by various chemo-attractants. Chemoattractants include lipids, 
peptides as well as proteins. These include classic neutrophil chemoattractant 
peptides such as fMLP that is a tripeptide of N-formylmethionyl-leucyl-
phenylalanine (fMet-Leu-Phe) [78]; complement cleavage products C5a and C3a 
that are involved in migration of various leukocytes [79] and lipid 
chemoattractants like leukotriene B4 (LTB4) and platelet activating factor (PAF) 
identified as strong chemoattractants for neutrophils. In addition a large family of 
protein chemoattractants or chemokines broadly divided into four groups i.e. CC, 
CXC, CX3C and the XC families based on the number and position of vicinal 
cysteine residues are potent chemoattractants for various leukocytes [40, 80]. 
Chemokines bind to G-protein coupled receptors with seven transmembrane 
domains. Differential receptor expression on immune cells is a crucial factor in 
determining responsiveness to chemokines. Around 50 chemokines and 20 
chemokine receptors have been identified to date [81]. This suggests that various 
chemokines and chemokine receptors bind to multiple counterparts suggesting 
functional redundancy and complex regulation of cell migration [82].  No 
chemokine is uniquely active on one particular leukocyte subset [83]. 




cells/epithelial cells but specific cell types are involved in chemokine production 
under specific inflammatory conditions. Usually, multiple chemokines are 
produced concomitantly in a redundant manner in response to the same stimulus 
by a cell, this phenomenon referred to as “polyspeirism” [83]. Two general modes 
of chemokine production; constitutive production (eg. SDF-1, CCL19, CCL13, 
CCL17, CCL25, etc.)  or inducible production upon activation (eg. CXCL10, 
CCL5, CCL3, CCL4, CCL2, IL-8, etc.) are defined [83]. Leukocyte migration is 
tightly regulated by spatial and temporal expression of chemokines [84].   
Chemokines regulate cancer development 
It is increasingly evident that a tumor is a complex microenvironment that 
constitutes various cell types including immune cells, stromal cells like 
fibroblasts, tumor cells and endothelial cells that communicate with each other. 
The composition of the tumor microenvironment in terms of the types of immune 
cells recruited decides whether anti-tumor or pro-tumor immune responses 
predominate and ultimately the fate of tumor development. Chemokine/cytokine 
mediated inflammation plays a crucial role in initiation and progression of various 
cancers [85]. Tumor cells also produce inflammatory chemokines and express 
chemokine receptors. Melanoma cells have shown to express various 
chemokines like CCL2, CCL5, CXCL1, CXCL2, CXCL3 and CXCL8 that are pro-
tumorigenic [81, 86]. It is well known that various cancer cells express CXCR4, 
chemokine receptor to SDF-1 and regulates the growth, migration and invasion 
of tumor cells by activating AKT, MAPK, and JAK-STAT pathways [87, 88]. Apart 




been involved in angiogenesis and metastasis of cancer as well. Chemokines 
like CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 activating 
CXCR1 and CXCR2 receptors have been shown to be promoters of 
angiogenesis [81].  
With respect to immune cells in the tumor mileu, CXCR3 receptor and its ligands 
CXCL9, and CXCL10 are strongly related to Th1 biased responses that is a 
crucial part of effector anti-tumor responses [89-91].  CXCR3-CXCL9/10 pathway 
is an important axis involved in CD4+, CD8+ T cell and NK cell infiltration to 
tumors for anti-tumor immunity. CXCR3 expression was also shown to be crucial 
to generate cytotoxic anti-tumorigenic M1 polarized macrophages [92]. Another 
chemokine receptor involved in CD4+ T cell mediated antitumor immunity is 
CCR5. CCR5 on CD4 and CD8+ T cells was shown to be crucial in anti-tumor 
responses as deficiency in CCR5 led to enhanced lung adenocarcinoma 
progression [81, 93].  
Tumor promoting cells are also governed through chemoattractant pathways. It is 
known that tumors shape the microenvironment to its advantage by recruiting 
immune suppressive cells like Treg cells, TAMs, MDSCs etc. Treg cells 
constitute a considerable portion of the tumor mileu and through the production 
of immune suppressive molecules like IL-10 and TGF-β are extremely potent in 
dampening the anti-tumor response [94]. CCR4-CCL22 axis is shown to be 
crucial in Treg recruitment to tumors, enhancing VEGF levels followed by 
angiogenesis and also cancer metastasis [95, 96]. CCR5 [97], CCR10 [98] and 




Treg recruitment to tumors. MDSC myeloid cell subset was shown to secrete 
chemokines like CCL3, CCL4, and CCL5 that lead to CCR5 mediated 
recruitment of Treg cells to tumors [97]. Apart from CCR5 chemokines, CCR2-
CCL2, CXCR2-CXCL5 and CXCR4-CXCL12 axis have been shown to promote 
tumor progression by enhancing the suppressive activity of TAMs and 
MDSCs [81] 
Chemoattractants recruit activated CD8+ T cells to target tissues 
The mechanisms of chemoattractant-regulated CTL migration to target tissues 
have been extensively investigated in the context of allergy, inflammation, 
autoimmune and infectious diseases, as well as in transplantation. However, 
limited information is available on CTL migration into tumors. Perhaps the 
knowledge on CTL migration in other diseases might guide further studies in the 
context of CTL migration to tumors.  
In preclinical models of allergic inflammation and airway hyper-responsiveness, 
the LTB4–BLT1 axis plays a critical role in controlling the migration of activated 
CTLs into the airway [100]. The induction of BLT1 in CTLs and BLT1 dependent 
chemotaxis in effector but not in naive or central memory cells was 
demonstrated. In addition to BLT1, chemokine receptors CCR5, CXCR3, CXCR6 
have all been implicated in CTL migration to lungs under pathophysiological 
conditions [101-103]. The role of CCR2 on CTLs in autoimmune systemic lupus 
erythematosus is well recognized; CCR2-deficient CTLs are unable to migrate to 




ligand CCL25 control CTL migration, including to the small intestine, during 
inflammatory bowel disease [101]. In patients with rheumatoid arthritis, the 
CX3CR1: CX3CL1 axis is involved in the recruitment of autoimmune CTLs to the 
synovium [105]. Migration of CTLs in CXCR6, CCR4 and CCR10 dependent 
fashion to inflamed skin in psoriasis is also well established [106]. Myelin specific 
CTLs migrate to multi pre-sclerotic lesions in a CXCR3 and CCR5 dependent 
manner [107]. Thus, a wide range of chemokines and their receptors appear to 
control CTL migration in a target tissue-dependent manner. This could have 
implications for CTL migration to tumors in different anatomical locations.  
An important physiological function of CTLs is to combat infections. The 
chemokine receptor CXCR3 and its ligands CXCL9/10 have been shown to 
mediate the recruitment of CTLs in a variety of infectious diseases [108, 109]. 
CXCL10 was recently shown to enhance CTL-mediated control of the pathogen 
Toxoplasma gondii in the brains of the chronically infected mice [110]. In a model 
of HCV and HSV-2 infections, CXCR3 and its cognate ligands mediated CTL 
infiltration to the inflamed liver [108] and vaginal mucosa [109], respectively. 
Chemoattractant mediated CTL migration is also an important part of the 
pathology of post-transplantation complications. It is well known that CCR5+ and 
CXCR3+ CTLs are involved in cardiac allograft vasculopathy and acute allograft 
rejection [111, 112]. In chronic rejection of lungs, CCL5, CXCL9, CXCL10, 
CXCL11 and CCL2 were upregulated, which might contribute to the post-
transplantation complications by recruitment of antigen-specific CTLs to the graft 




was mainly controlled by CXCR6 [113]. Hence, chemokines/ chemokine 
receptors are an integral element of CTL recruitment and present an attractive 
pharmacological target for intervention in various disease pathologies.  
Recent advances in the imaging techniques, such as intravital microscopy, have 
allowed in vivo tracking of CTLs in real time to gain some insights on CTL 
migration to tumors. It has been demonstrated that recognition of cognate 
antigen by CTLs within tumors is a critical determinant of optimal CTL infiltration 
and killing of tumor cell [114]. Furthermore, CD44 dependent CTL migration 
within the tumor microenvironment was found to be an essential immunologic 
checkpoint that determines the potency of T-cell effector functions [115]. 
Boissonnas et al. showed that activated CTLs migrate at high instantaneous 
velocities in the periphery, but get arrested when in close contact with tumor cells 
expressing their cognate antigen; therefore, antigen expression by tumor cells 
determines both CD8+ T cell motility within the tumor and extent of tumor 
infiltration [116]. In this regard, Deguine et al. demonstrated a sharp contrast 
between the effector function of CTL and NK cells. Although NK cell formed 
dynamic contacts with tumor cells, CTLs formed stable contacts with tumor cells 
expressing their cognate antigen for exerting their cytotoxic functions [117]. 
Dense matrix was shown to resist the CTL migration because aligned fibers in 
perivascular regions and around tumor epithelial cell regions dictated the 






Chemokine receptors controlling activated CTL migration to tumors 
Several studies with human cancers showed a strong correlation between CD8+ 
T cell infiltration and long-term survival [119]. The newly activated CTLs must 
infiltrate the tumor to exert their cytotoxic effects for controlling tumor growth [40]. 
Among the many factors controlling CTL migration, chemoattractants play a 
pivotal role in shaping the intratumoral infiltration of activated CTLs. The release 
of individual chemokines, such as CCL3, CCL5, CCL20, CXCL10, CXCL16 and 
CX3CL1 at the tumor site was shown to enhance CTL recruitment and antitumor 
immunity, confirming their important role in this process [40]. Likewise, the 
chemokine receptors known to be crucial in CD8+ T cell recruitment to tumors till 
date are CX3CR1, CXCR6, CCR5 and CXCR3. Because of it’s relevance in this 
thesis, CXCR3 will be described in detail. We have reviewed all these chemokine 
receptors in detail here [40].   
CX3CR1: 
The CX3CL1/CX3CR1 axis has been associated with high numbers of infiltrating 
CTLs and better prognosis in colorectal cancers [120]. CX3CL1 (fractalkine) 
gene transfer in tumor cells also showed marked antitumor activity primarily by 
enhancing the infiltration of T and NK cells in various cancers, [40, 121-123], as 
also DC maturation and activation in the tumors [124]. 
CXCR6: 
Another relatively new player in this context is CXCL16, which was produced by 




enhanced the recruitment of CXCR6- positive CTLs and thus anti-tumor immunity 
[40, 125, 126].  
CCR5  
CCR5 was the first chemokine receptor that was shown to be an important 
regulator of CTL trafficking to tumors because its cognate ligand facilitated the 
infiltration of CTL into tumors [127]. Intratumoral injection of a chimeric CCL5-Ig 
encoding DNA plasmid was associated with the infiltration of increased numbers 
of NK, CD8+ and CD4+ T cells and generation of effective antitumor immunity. 
This effect was lost in RAG-2 or CCR5-deficient mice, indicating that CCR5 
dependent CTL migration was required for this antitumor effect [128]. Adenoviral 
gene transfer to induce CCL3 expression in B16-ova tumors in vivo increased the 
efficacy of adoptively transferred tumor-specific effector OT1 T cells expressing 
its cognate receptor CCR5 [93, 129]. However, in human cancers, the role of 
CCR5 and its cognate ligands has been elusive because of the diverse 
observations in various types of cancers. For example, in lung cancer, CCL5 is 
associated with favorable disease prognosis [130] but in breast, cervical and 
colon cancers, CCL5 has been associated with adverse prognosis [131, 132]. In 
case of colon cancer, tumor-derived CCL5 has been demonstrated to recruit 
regulatory cells and enhance the ability of these cells to induce apoptosis in 







It has long been recognized that CXCR3 is an important chemokine receptor for 
controlling CD8+ T cell migration under diverse pathophysiological conditions, 
including tumors. Expressed on antigen-activated CTLs, this receptor recognizes 
three cognate ligands, which are interferon-inducible proteins; CXCL9, CXCL10 
and CXCL11, produced by stromal cells including endothelial, epithelial and 
tumor cells in response to IFNγ. CXCR3 has been extensively studied in 
autoimmune and viral diseases and recently in cancer. CXCR3 gene Cxcr3 is 
located on the sex-chromosome and is an X-linked gene both in mice and 
humans [133]. Since certain immune disorders like systemic lupus 
erythematosus (SLE) have increased incidence in females compared to males, 
there may be a possible CXCR3 dependent gender predisposition to certain 
immune disorders. Hyun et.al. have reported a possible correlation of 
c.12+234G>A polymorphism in CXCR3 with asthma development especially in 
males [134]. Another study reported an association of the CXCR3 polymorphism 
rs34334103 with male patients with SLE and pleuritis development in those 
patients [135]. 
There may however In SP2/0 myeloma tumor model, CXCL10 expression via 
adenoviral gene transfer in combination with adoptive T-cell therapy completely 
eradicated the tumors, whereas both the adoptive T-cell therapy and CXCL10 
adenoviral gene transfer treatments had minimal to no beneficial efficacy [136]. 
These results highlight the importance of the ligand (CXCL10) in tumors and the 




antitumor immunity. In the case of human renal cell carcinoma, intratumoral 
expression of chemokines CXCL9 and CXCL10 showed positive correlation with 
CTL infiltration and inverse correlation with tumor size. Moreover, it was also 
observed that tumors that expressed CXCL9/10 rarely recur after surgery, 
reinforcing the role of these pathways in antitumor immunity [129]. In a 
retrospective evaluation of melanoma tumors isolates, expression of CXCR3 by 
human CTLs was significantly associated with enhanced survival in stage III 
patients [137]. Human melanoma cell lines have been shown to secrete CXCR3 
ligands in response to IFNγ [138]. Analysis of the chemokines and their receptor 
expression using immunohistochemistry and flow cytometry in situ in colorectal 
patient’s samples revealed pre- dominant IFNγ positive CTLs co-expressing 
CCR5 and CXCR3 receptors [139]. In human hepatocellular carcinoma (HCC), it 
was shown that CXCR3 expression correlated with activation markers, such as 
CD69, and it was suggested to be an important receptor of CTL migration [140]. 
Conversely, another study on HCC showed functional desensitization of CXCR3 
in lymphocytes, including CTLs from HCC patients, by CXCL10 secreted by 
tumor cells suggesting a new mechanism in HCC to induce dysfunction of active 
CTL migration and subsequently impaired immune defense against the tumor 
[141]. These studies emphasize the importance of the CXCR3-CXCL9/10 axis in 
generating antitumor immunity in mouse models and in multiple human tumors. 
Mikuchi et.al. recently elegantly demonstrated CXCR3 mediated signalling to be 
a critical and an indispensable checkpoint for tumor antigen specific CD8+ T cells 




activity in mice and human melanoma [142]. CTL chemokine receptors CCR5 
and CCR2 were not essential for CXCR3 mediated CTL extravasation across 
tumor vessels despite the presence of CCL2 and CCL5 chemokines in the tumor 
mileu. A recent study demonstrated that adenosine in the tumor milieu 
suppressed the production of CXCL10 followed by suppression in T cell 




























Figure 2: Chemokine network in the anti-tumor immune response. Malignant 
cells express pathogen-associated molecular patterns (PAMP) that can be 
recognized by pattern recognition receptors (PRR) on dendritic cells (DC) and 
macrophages (M), triggering release of chemokines.This results in recruitment 
and activation of M, NK, and NKT cells, which are able to lyse tumor cells. DC 
phagocytoses apoptotic tumor cells and HSP-complexed tumor-derived peptides. 
Upon maturation, DC change their homing proprieties by downregulating tissue-




CCL19/CCL21-rich lymph nodes (LN), where they present processed tumor 
peptides to CD4+ and CD8+ T cells. Activated T cells upregulate expression of 
chemokine receptors including CCR5 and CXCR3, and in response to 
intratumoral chemokines, circulating CTL infiltrate the tumor to destroy malignant 
cells 
















Chemoattractants & their receptors as targets for enhancing CTL 
recruitment 
Poor CTL trafficking to tumors has become the rate-limiting step in the success 
of immunotherapies as suggested by evidence from clinical trials [40, 75, 76, 
145, 146]. Recently, there have been studies showing modulation of chemokine 
or chemokine receptor expression to enhance CTL migration to tumors [77, 122, 
147-149]. Activation of Toll-like receptors 3 on mast cells through Poly-IC-
induced CXCL10 and RANTES production leads to an increase in CTL 
recruitment [150]. IL-12 treatment of a fibrosarcoma and ovarian cell-derived 
tumor resulted in tumor regression via CCR5 dependent CTL migration [151]. 
Ionizing radiation enhanced the recruitment of CXCR6+ CTLs and antitumor 
response in 4T1 breast cancer mouse model [125].  In a recent study, combining 
radiotherapy and ipilimumab resulted in abscopal effects in a treatment-refractory 
lung cancer patient that correlated with enhanced CTL infiltration [152]. 
Chemotherapy, such as low-dose cyclophosphamide and gemcitabine, can 
eliminate the T regulatory cells [153] and MDSCs [154] respectively, allows for 
the production of immunostimulatory antitumor cytokines, such as IFNγ and TNF-
α, which can induce the CXCR3 and CCR5 mediated feed-forward recovery of 
CTL recruitment. Radiation therapy, along with its direct cytotoxic effect, also has 
an immunomodulatory effect through interferon-induced chemokine CXCL10 
production by the myeloid cells in tumors. CXCL10 increases CXCR3 mediated 




Direct modulation of CCL5 in the tumor environment was found to enhance CTL 
infiltration and tumor rejection in an immunogenic fibro- sarcoma genetically 
modified to express CCL5 in murine model [148].  
Various CAR-based therapies using chemokine receptors have been used to 
enhance the recruitment of tumor specific CTLs into tumors. For instance, in a 
CAR-based ACT for mesothelioma, the infiltration of human T cells in tumors 
injected with untransduced T cells or with the mesoCAR T cells was very low 
(~0.3–0.4%) and not significantly different. In contrast, the infiltration of 
transferred mesoCAR + CCR2b gene modified T cell group was dramatically 
improved to 5.2% (>12.5-fold) when compared with the mesoCAR or the 
untransduced T cell groups [77].  
The Reed–Sternberg cells of Hodgkin lymphoma produce CCL17 and CCL22, 
recruiting CCR4+ T regulatory cells to tumor-causing immune suppression [156]. 
Modification of CTLs instead, to express both CAR directed to the Hodgkins 
lymphoma associated antigen CD30 and CCR4 resulted in >10-fold increase in 
tumor infiltration of CTLs by day 12. Infusion of these cells intravenously caused 
tumor regression in 57% of the mice [156]. These directed therapies enhanced 
the antitumor responses of the CAR CTLs and also increased the effective 
migration of these cells into the tumors.  
CTL migration to tumors was enhanced by transfecting the CTLs with 
photoactivable chemokine receptor (PA-CXCR4) that induced their homing to 




the use of photoactivatable chemokine receptors as an important tool to enhance 
CTL recruitment, particularly in CTL based therapies, such as adoptive T cell 
transfer therapies [157]. All of these studies demonstrate the potential for 
targeting the chemokine/chemokine receptor directly or indirectly to enhance CTL 
cell migration into tumors and thus T cell mediated immunotherapies.  
Barriers to CTL infiltration to tumors 
The tumor evades the immune control by manipulating the immune system into 
supporting its growth, including restricting the CD8+ T cell infiltration into the 
tumor microenvironment [40, 158]. Anti-tumor cytokines like IFNγ have shown to 
be crucial for T cell homing to tumors [159]. However, the tumor mileu is largely 
immune-suppressive instead due to expression of molecules like TGF-β, IL-10, 
IDO, VEGF-A, adenosine, etc. that compromise T cell recruitment process [75]. 
Mechanisms by which T cell homing to tumors gets abrogated  is discussed 
below. 
The immune-suppressive environment not only hinders T cell homing to tumors, 
but those that enter are restricted at the tumor margins or periphery. Studies in 
breast cancer model showed that tumor dendritic cells (Tu-DCs) and tumor 
associated macrophages (TAMs) constitutively cross present the tumor antigens 
to the infiltrating tumor specific T cells engaging them with long-unproductive 
interactions at the tumor margin [160]. Another study demonstrated that 
adoptively transferred T cells were trapped in TuDC-mesh like structures that 




Cytotoxic cell to tumor cell ratio is critical for anti-tumor immunity. T cells are 
present in higher numbers in tumors that express chemokines like CXCL9, 
CXCL10, CCL2, CCL3, CCL4 and CCL5 [162]. Tumors usually alter the 
chemokine profile thus disturbing the balance between T cells and tumors. 
Tumor mileu can potentially induce chemical modification of chemokines thereby 
rendering them non-functional for CTL recruitment. For example, nitrosylation of 
CCL2 preferentially recruits MDSCs and not tumor specific T cells [163]. Likewise 
tumors under hypoxia also produce CCL28 that preferentially recruit the Tregs 
[98]. Aberrant EGFR-Ras signaling in skin tumors was shown to suppress the 
production of CCL27 chemokine by keratinocytes and absence of CCL27 was 
shown to prevent T cell infiltration to tumors and anti-tumor immunity [164]. 
Another mechanism for preventing CTL infiltration was postulated to be due to 
altered proteolytic processing of the CXCR3 chemokine CXCL11 [165]. Thus 
tumor strategizes immune evasion in various ways including alteration of 
chemokine production to prevent CD8+ T cell infiltration to tumors. 
Yet another mechanism that prevents T cell recruitment to tumors is the 
disorganized and aberrant nature of the tumor associated endothelial vessels. 
Growth factors in the tumor mileu like endothelin 1, basic fibroblast growth factor 
(bFGF) and VEGF-A blocks/downregulates the expression of ICAM1 and 
VCAM1; a phenomenon called “Endothelial cell anergy”.  This leads to 
attenuation of T cell adhesion to tumor endothelium and thereby prevents their 
infiltration into tumors [75, 166]. Although the tumor endothelium is considered as 




cancer study, it was reported that VEGF expression was three folds more in 
tumors without T cells than with T cells [167]. Angiogenesis in the context of 
tumor leads to the generation of new tumor vessels that are quite irregular 
compared to the normal vessels. The tumor vessels that originate from the 
existing ones in the tumors are leaky, disorganized, dilated with abnormal 
structural morphology, absent or loosely attached pericytes and unusually thick 
basement membrane [146, 168]. This abnormal nature of the tumor vasculature 
may increase the interstitial pressure and promote aberrant blood flow making it 
difficult for selective leukocytes to adhere and traffic into the tumor mass even 
after being activated in the periphery.  
Absence of certain chemokine receptors can seriously compromise T cell homing 
to tumors. Importance of chemokine-chemokine receptor systems in regulating 
CD8+ T cell homing to tumors is only recently being acknowledged. Apart from 
the chemokine receptors discussed in the previous section there are no other 
known chemokine-chemokine receptor systems that are known to be crucial for 
CD8+ T cell recruitment into tumors and hence necessitates research in this area. 
Targeting chemokine-chemokine receptor pathways can enhance T cell homing 
to tumors. Recent studies have indicated the presence of tumor specific T cells in 
the tumors for the immunotherapies to be successful. In fact the data presented 
in this thesis indicate that PD-1 blockade based immunotherapy completely fails 
in BLT1-/- and CXCR3-/- mice suggesting the importance of chemokine receptors 





Leukotriene B4 and its high affinity receptor BLT1 
Leukotriene B4 (5(S), 12(R)-dihydroxy-6, 14-cis-8, 10-trans-eicosatetraenoic acid, 
LTB4) is a potent lipid inflammatory mediator, a calcium ionophore, that causes 
adhesion and chemotactic movement in leukocytes and stimulates aggregation, 
enzyme release and superoxide generation in neutrophils [169, 170]. LTB4 is 
derived from arachidonic acid released from membrane phospholipids via the 
actions of phospholipase A2. Enzymes 5-lipoxygenase (5-LO) [171] and LTA4 
hydrolase [172] catalyze the production of LTB4 from arachidonic acid in a 
sequential manner. While LTA4 hydrolase is universally present in all cells, 5-
lipoxygenase is only expressed in hematopoietic cells mostly myeloid cells. LTB4 
is produced by myeloid cells mostly, however, under inflammatory condition, 
LTB4 production in other cells (non-immune cells) have also been reported via 
transcellular transport of LTA4 from immune cells at the site of inflammation to 
other cells that have LTA4 hydrolase activity [173]. LTB4 signals through two G 
protein coupled seven-transmembrane domain receptors, BLT1 and BLT2, the 
high and low affinity receptors, respectively [174-176]. BLT1 receptor activation 
upon ligand binding leads to IP3 mediated calcium release from intracellular 
portions and later calcium influx through the cell membrane. In general, BLT1 
receptor enhances the production of inositol phosphates, mobilize intracellular 
calcium, and activate several kinases, including PI3K, MAPK and AKT [177]. 
BLT1 is expressed on a variety of immune cell subsets including neutrophils, 




BLT1 as a pro-inflammatory mediator was first known when BLT1 deficient mice 
showed significantly reduced arachidonic-acid induced ear inflammation [179].   
The protective phenotype observed in BLT1 knockout mice in various 
inflammatory disease models like asthma, atherosclerosis, arthritis, autoimmune 
uveitis, and diet-induced obesity later on indicated that BLT1 mostly acts as a 
pro-inflammatory mediator [180-184].  However, BLT1 mediated migration of 
different cell types were the causative reasons behind each of these diseases. 
For example, BLT1 mediated recruitment of neutrophils was crucial for arthritis to 
develop; macrophage recruitment via BLT1 was crucial in atherosclerosis and 
diet induced obesity manifestation; and BLT1 mediated recruitment of activated T 
cells in the development of autoimmune uveitis and airway-hyperresponsiveness. 
The biological significance of this receptor in antitumor immunity has not been 
explored. The majority of work carried out in the context of inflammatory, 
autoimmune diseases demonstrated that CD8+ T cells inducibly express BLT1 
upon activation and the receptor expression is essential for their recruitment to 
target organs and disease development [100]. In a model of autoreactive T cell–
induced uveitis, BLT1 expression on both T cells and innate immune cells was 
found critical for full disease development, and absence of BLT1 is highly 
protective in ocular inflammation [183]. However, in the context of cancer, the 
lack or delay in recruitment of effector immune cells such as T cells may delay 
generation of immune response to tumor Ag that can lead to breach of immune 




To determine the role of BLT1 in anti-tumor immunity, implantable model of TC-1 
cervical cancer was employed and the data from these experiments is briefly 
described and formed the basis for the experiments conducted in the current 
thesis. The results obtained after challenging WT and BLT1 deficient mice with 




















LEUKOTRIENE B4 RECEPTOR, BLT1 REGULATES ANTI-TUMOR IMMUNITY 
BY MEDIATING CD8+ T CELL INFILTRATION TO TUMORS 
BLT1 the high affinity receptor for Leukotriene B4 has long been identified as a 
pro-inflammatory mediator in various disease models of infection, auto-immunity, 
inflammation and tumors. BLT1 is expressed on a variety of immune cells as 
discussed before. Migration of specific cell types is crucial in determining the type 
of inflammation (pro or anti-tumor growth) that ensues. Infiltration of CD8+ T cells 
into the tumors is a critical event for effective antitumor immunity.   
The results presented in this section details the role of BLT1 in regulating CD8+ T 
cell infiltration to tumors and anti-tumor immunity using a viral antigen based 
subcutaneous implantable TC-1 cervical cancer model [176]. Implantation of 
2x104 TC-1 cells resulted in development of tumors only in 50% of WT mice (sub-
lethal dose). However, under these conditions, 100% of BLT1-/- mice developed 
tumors. At this dose, while 100% of BLT1-/- mice succumbed to disease by day 
50, 60% of WT mice still survived at day 80-post tumor challenge (Figure 3A). 
Subcutaneous implantation of 105 TC-1 cells (lethal dose) also resulted in 
significantly enhanced tumor growth and reduced survival in BLT1-/- mice 
compared to WT mice (Figure 3B and C). These results indicated that BLT1 




Development of cancer is proposed to be the end result of a malignant 
transformation that has passed through all three phases viz. elimination, 
equilibrium, and escape phases [18]. The data obtained with lethal and sub-lethal 
doses of tumor cells suggest a crucial function for BLT1 in controlling both 
elimination and equilibrium phases of tumor development. The sub-lethal dose of 
tumor led to slow growing tumor formation in only 50% of WT mice but showed 
tumor development in 100% of the BLT1 deficient mice suggesting that BLT1 is a 
crucial component of immune surveillance to tumors. The lethal dose of tumor 
cells led to rapidly growing tumors in BLT1-/- mice, indicating its function in 
antitumor immunity [176]. 
To determine the cellular mechanisms behind this phenotype, tumor immune 
infiltration studies were carried out. A marked decrease in infiltration of overall 
CD45.2+ immune cells with most striking decline in CD8+ T and NK cell 
population in tumors of BLT1−/− mice compared with WT (Figure 4A – 4C) was 
observed. To ensure that this difference was not a function of enhanced tumor 
size in BLT1-/- mice; CD8+ T cells at similar tumor sizes were stained that also 
showed significant reduction of CD8+ T cells in tumors of BLT1-/- mice compared 
to WT mice (Figure 4D). Also no significant difference in CD8+ T cell numbers 
was observed in spleen and tumor draining lymph nodes of WT and BLT1-/- mice 
(Figure 4E and 2F) suggesting that BLT1 deficient CD8+ T cells showed 
defective tumor infiltration ability. Gene expression analysis by RT-PCR showed 
a significant reduction in effector T cell transcript levels such as IFN-γ, granzyme 




To understand whether BLT1 expression on CD8+ T cells or NK cells is crucial in 
the observed phenotype; BLT1-/-RAG2-/- mice were generated by crossing BLT1-/- 
mice with Rag2-/- mice. Comparison of tumor growth kinetics in Rag2-/- and BLT1-
/-Rag2-/- mice revealed no significant differences in tumor growth indicating that 
BLT1 expression on innate cells including NK cells does not play a dominant role 
in this model. Also, similar levels of NK cells were seen in tumors of Rag2-/- and 
BLT1-/-Rag2-/- mice (Figure 5A and 5B) [176]. Although NK cells by themselves 
may not hinder tumor growth in this model, it is still possible through CD8–NK 
cross talk that they contribute to effective antitumor immunity [185].  
To further understand the importance of BLT1 on CD8+ T cells, CD8+ T cells 
were depleted in WT and BLT1-/- mice following TC-1 tumor challenge using CD8 
depleting antibody (Bioxcell).  Depletion of CD8+ T cells resulted in a significant 
acceleration of tumor growth only in WT and not in BLT1−/− mice. Moreover, the 
tumor growth in the CD8-depleted WT mice nearly overlapped with the tumor 
growth in BLT1−/− control mice and/or CD8+ T cell–depleted BLT1−/− mice (Figure 
6). Therefore, elimination of CD8+ T cells alone was sufficient for complete loss 
of the observed phenotype, implicating a central role for BLT1 expression on 
CD8+ T cells.  
Adoptive transfer of tumor experienced WT but not BLT1-/- CD8+ T cells 
intravenously could significantly reduce tumor growth in Rag2-/- mice challenged 
with TC-1 tumors (Figure 7). This experiment served as a simplified replica of 
the adoptive T cell therapy used in the clinic following immune ablation. CTL 




tumors in greater numbers compared to BLT1-/- CD8+ T cells; their numbers 
being similar in the tumor draining lymph nodes (Figure 7B and 7C). Analysis of 
the major CD8+ T cell chemokine receptors, CCR5, CCR9, CXCR3 and BLT1 on 
the transferred WT and BLT1-/- CTLs in TdLN and tumor revealed no striking 
differences besides the significantly enhanced expression of BLT1 on WT CTLs 
in TDLNs compared to the absence of its expression in naive WT and BLT1-/- 
CTLs (Figure 8). A significant increase in CXCR3 expression was observed in 
both adoptively transferred WT or BLT1-/- CD8+ T cells relative to the CD8+ T cells 
from the naïve mice. Analysis of expression of all these receptors on CD8+ T 
cells showed complete downregulation in tumors which is consistent with our 
previous study and many others suggesting receptor internalization upon ligand 













Figure 3: Decreased survival and increased tumor growth in BLT1-/- mice. (A 
and B) Significantly reduced survival of BLT1-/- mice using sub-lethal and lethal 
TC-1 dose. Kaplan–Meier survival plots of BLT1+/+ and BLT1-/- mice. (A) The 
mice were injected s.c. with a sublethal dose (2.0 x 104) of TC-1 cells and their 
survival was monitored up to 80d. (B) BLT1+/+ and BLT1-/- mice were injected s.c. 
with a lethal dose (1.0 x 105) of TC-1 cells and survival was followed. (C) 
Significantly enhanced tumor growth in BLT1-/- mice. Tumor size in lethal dose 
challenged group was measured and calculated by multiplication of two 
perpendicular diameters (length x width). Log rank tests were performed for 
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Experiment shown is representative of three independent experiments. *p< 0.05 









                
 
 
Figure 4: Reduced infiltration of effector antitumor immune cells into TC-1 
tumors growing in BLT1-/- mice. (A–C) BLT1+/+ and BLT1-/- mice were injected 
s.c. with 1.0 x 105 TC-1 cells, and tumors were harvested at 29d of post tumor 




































































































































































cells (C) per million of total tumor cells were analyzed from WT and BLT1-/- mice 
using standard flow cytometry methods. (D–F) CD8+ T cell staining in size 
matched tumors showing %CD8+ T cells (frequency of total) in tumor (D),  % 
CD8+ T cells (frequency of CD45+) in TdLN (E), and spleen (F) from WT and 
BLT1-/- mice. (G-I) Quantitative real-time PCR analysis:  The levels of IFNγ (G), 
granzyme B (H), and IL-2 (I) mRNA expression in BLT1-/- tumors as compared 
with WT tumors by qRT-PCR were determined. Data are representative of two to 
three independent experiments involving at least n = 4 mice/group in each 










      
Figure 5: Unaltered tumor growth and intratumoral NK cell numbers in 
Rag2-/- and   Rag2-/-BLT1-/- mice. (A) Rag2-/- and   Rag2-/-BLT1-/- mice were 
challenged s.c. with 5 x 104 TC-1 cells on the right flank and observed for the 
rate of tumor growth. (B) Absolute numbers of tumor-infiltrating NK cells per 
million of total tumor cells were analyzed from Rag2-/- and   Rag2-/-BLT1-/- mice 
using standard flow cytometry methods.  Data shown are representative of three 
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Figure 6: Depletion of CD8+ T cells accelerates TC-1 tumor growth in 
BLT1+/+ but not in BLT1-/- mice. A single dose of 500 µg CD8-depleting Ab was 
injected i.p. in WT and BLT1-/-mice. The next day, 1 x 105 TC-1 tumor cells were 
inoculated s.c in the right flank in WT and BLT1-/- mice, and the tumor growth 
was monitored. Data shown are representative of three independent 




































Figure 7: Adoptive transfer of tumor primed CD8+ T cells from BLT1+/+ but 
not from BLT1-/- mice retards tumor growth. Rag2-/- mice were challenged with 
5 x 104 TC-1 tumor cells in the right flank. Two days later, CD8+ T cells were 
isolated from the spleens and lymph nodes of tumor bearing (3–5 mm) WT or 
BLT1-/- mice by magnetic sorting. A total of 8 x 105 CD8 T cells (97% purity) or 
PBS was injected i.v. in the tumor inoculated Rag2-/-mice. (A) Tumor growth 
curve of Rag2-/-, Rag2-/- transferred either with BLT1+/+ or BLT1-/- CD8+ T cells. (B 
and C) The %CD8+ T cells of total cells recovered from TDLNs (B) and %CD8+ T 
cells of total CD45+ cells within tumors (C) are shown. Data shown are 




















































































Figure 8: Chemokine receptor expression on the adoptively transferred 
CD8+ T cells from TDLNs and tumors. Adoptively transferred CD8+ T cells from 
WT and BLT1-/- mice into Rag2-/- mice were analyzed for the expression levels of 
chemokine receptors. Naïve WT and BLT1-/- CD8+ T cells were used as controls. 
Chemokine receptors CCR5, CCR9, CXCR3, and BLT1 were stained and 
analyzed on the transferred CD8+ WT or BLT1-/- CD8+ T cells from TDLNs (A) 








Taken together, using an implantable cervical cancer model, we demonstrated 
that expression of BLT1 on CD8+ T cells plays a crucial role in mediating their 
recruitment to tumors, thereby initiating and sustaining antitumor immunity. In the 
context of cancer, BLT1 was shown to play a dual role in controlling tumor 
promoting inflammation; as seen in silica induced lung tumorigenesis [186] and 
or tumor suppressive inflammation; as shown in the TC-1 cervical cancer model 
[176]. A recent article by Yokota et al. used GM-CSF–based tumor vaccine 
setting in BALB/c leukemia model to evaluate the vaccine and secondary/recall 
immune responses. Their results showed similar or better primary and recall 
immune responses in the BLT1−/− mice [187]. Several differences that might 
account for the divergent results include: 1) different mouse strains (BALB/c), 2) 
different cancer type (leukemia), and 3) GM-CSF transformed cancer cell lines. 
In addition, Yokota et al.’s study found differences WT and BLT1−/− mice only in 
the recall responses with CD4+ T cells playing a dominant role. In our studies, the 
numbers of tumor-infiltrating CD4+ T cells in WT and BLT1−/− mice were similar, 
indicating a limited, if any, direct role of CD4+ T cells in controlling the tumor 
growth.  
Hence, in context of cancers, BLT1 seems to have dual roles in tumor 
progression. Given the results on the role of BLT1 in CTL migration to tumors in 
viral antigen based cervical cancer model, the experiments conducted in this 
thesis are aimed at developing an understanding about the role of BLT1 in 
endogenous immune surveillance against other solid tumors, specifically non-




CXCR3 chemokine receptor in CTL migration to tumors and anti-tumor immunity 
and the possibility of interdependence of BLT1 and CXCR3 in achieving an anti-
tumor immune response through the generation of BLT1/CXCR3 double 
knockout mice (DKO).  The experiments also determine the importance of BLT1 
and CXCR3 receptors in regulating PD-1 blockade based therapeutic vaccinate 




















MATERIALS AND METHODS 
 
Mice and cell lines:  
C57BL/6 mice, CXCR3-/- mice and UBC-GFP mice in C57BL/6 background (6-
7wks old) were purchased from The Jackson Laboratory and/or bred in our 
animal facility at the University of Louisville. Previously described BLT1-/- mice in 
C57BL/6 background were also bred in our animal facility at University of 
Louisville [179]. Rag2-/- mice in C57BL/6 background were purchased from 
Taconic (Germantown, NY). BLT1-/-CXCR3-/- double knockout mice were 
generated by crossing BLT1-/- and CXCR3-/- mice at our animal facility. All 
animals were cared for in accordance with institutional and National Institute of 
Health guidelines and under IACUC protocol. B16 melanoma cell line was 
purchased from American Type Culture Collection (Manassas, VA) and cultured 
in complete RPMI media supplemented with 10% FBS.  
Reagents:  
Fluorochrome-conjugated Abs (anti-CD45.2-PE-Cy7, anti-CD3-APC-Cy7, anti-
CD4-APC, anti-CD8-PerCP-Cy5.5, NK1.1-PE, CD11b-APC, Ly6G-PE, Ly6C-




were purchased from BD PharMingen and eBioscience. Trp-2 peptide (Trp2180: 
SVYDFFVWL) was purchased from Peptide 2.O Inc. Anti-mouse BLT1 antibody 
conjugated to biotin was developed in the lab (unpublished data).  Anti-m-OX-40 
agonistic Ab (Clone OX-86) and Anti-m-PD-1 antagonistic Ab (Clone: RMP1-14) 
were purchased from BioXcell. RT primers for IFN-γ, granzyme B, and IL-2 
genes were obtained from Real Time Primers, LLC. 
Tumor model and vaccinations:  
Naive WT, BLT1-/-, CXCR3-/- and BLT1-/-CXCR3-/- mice were challenged with 105 
live B16 melanoma cells by reconstituting in 200 μl PBS and injecting 
subcutaneously at the right flank of mice to form tumors. For sub-lethal tumor 
dose experiments, 4x104 live B16 cells were injected s.c. Tumor diameter was 
measured every alternate day using a calliper. Average tumor diameter was 
calculated by measuring two perpendicular diameters and tumor area was 
calculated by multiplying the two perpendicular diameters. For survival 
experiments, mice were allowed to reach 15 mm tumor diameter as experimental 
endpoint. Percentage survival was calculated and plotted using Kaplan Meier 
survival plots. Tumor bearing animals were euthanized once the tumors reached 
15 mm or 7-9 mm diameter or earlier if they showed any signs of discomfort. For 
in vivo-cytotoxicity studies, animals were immunized s.c. with 50 μg/mice Trp-2 
peptide and 100 μg/mice OX-86 Ab (Clone OX-86, BioXcell) in PBS or PBS 
alone as control. For vaccination studies; WT, BLT1-/-, CXCR3-/- and BLT1-/-
CXCR3-/- were challenged with 105 live B16 cells s.c. on the right flank on day 0.  




50 μg/mice Trp-2 peptide and 100 μg/mice anti-PD-1 antagonistic Ab (clone 
RMP1-14, BioXcell). The control mice were administered with PBS. The tumor 
growth was monitored every alternate day. The mice were euthanized when the 
knockout animals or the control unvaccinated animals reached 15 mm tumor 
diameter. Tumors, blood, spleen and tumor draining lymph nodes (TdLN) were 
then analyzed for CD8+ T cells by flow cytometry. 
Flow Cytometry:  
Tumors were harvested and cut into small pieces after removal of connective 
tissue and tissue stroma. To obtain single cell tumor suspension, the small tumor 
pieces were incubated in an enzyme mixture consisting of Collagenase A (2 
mg/ml) and DNase-I (1 mg/ml) in incomplete RPMI medium for 1hr at 37 °C on a 
rocking platform. After 1hr digestion, single cell suspension was obtained by 
passing the digested tissue through 40μm nylon mesh and the resultant cells 
washed twice in PBS before staining for flow cytometry. Cells were stained with 
fluorochrome labelled anti-mouse Ab like CD45.2, CD3, CD4, CD8, NK1.1, 
CD11b, Ly6G, Ly6C, etc. Two million total tumor cells were stained and analyzed 
using multi-parameter flow cytometry. Similarly, spleen and tumor draining lymph 
nodes (TdLN- inguinal, brachial and axillary) were harvested, processed into 
single suspension, stained and analyzed via flow cytometry. For intracellular 
cytokine staining single cell suspensions from tumor, spleen and TdLNs were 
stimulated with cell stimulation cocktail (eBiosciences, 500X used at 1X) 
consisting of PMA (40.5 μM), Ionomycin (670 μM) and protein transport inhibitors 




hrs the cells were harvested and washed, surface stained with CD45, CD3 and 
CD8 and fixed and permeabilized (IC fixation and Permeabilisation buffer – 
eBiosciences) and stained for IFNγ and TNFα using anti-mIFNγ Ab and anti-
mTNFα Ab (BD Biosciences). Isotype controls with the same fluorochrome were 
used as controls. Cells were acquired using FACS Canto II machine and 
analyzed by FlowJo (TreeStar) software.  
Immune-fluorescence microscopy: 
Immune-fluorescence staining for CD8+ T cells in the tumors of WT, BLT1-/- and 
CXCR3-/- mice was analyzed using Nikon-A1R Confocal microscope. Tumors 
were embedded in OCT medium and snap frozen in liquid nitrogen and later cut 
into 5 µm sections using a cryostat. Sections were fixed using ice-cold acetone 
and then blocked using 1X PBS supplemented with 3% BSA and 5% goat serum 
for 1 hr at RT. To stain for CD8+ T cells, the sections were incubated with rat anti-
mouse CD8a Ab (BD Pharmingen) in 1X PBS + 3% BSA for 1hr at RT. After 3 
washes with PBS, the sections were then incubated with the secondary Ab goat 
anti-rat Alexa 594 (2mg/ml, Invitrogen). After washing with PBS, the sections 
were mounted with Vectashield mounting medium containing DAPI (Vector Labs) 
and analyzed at 200X magnification. A minimum of 4 fields for each tumor 







Total RNA from the excised tumors was isolated using Trizol followed by RNase 
mini prep kit from Qiagen. The RNA was treated with DNase using Turbo DNAse 
kit (Ambion). For quantitative real-time PCR, 1μg total RNA was reverse 
transcribed in 50 μl reaction using TaqMan reverse transcription reagents 
(Applied Biosystems) using random hexamer primers. A total of 2 μl cDNA and 
the 1 μM real-time PCR primers were used in a final 20 μl PCR reaction with 
“power SYBR-green master mix” (Applied Biosystems). The real-time primers 
were purchased from Real Time Primers, LLC (Elkins Park, PA). The sequence 
of the primers will be provided upon request. Real-time PCR reaction was 
performed in Bio-Rad CFX-96 Real Time System. Expression of the target genes 
was normalized to GAPDH and displayed as fold change relative to the WT 
sample. Data are representative of tumors isolated from at least five different 
mice for each genotype. 
In vivo cytotoxicity assay: 
 A standard in vivo-cytotoxicity assay was performed by injecting peptide pulsed 
target cells into immunized mice as previously described [176]. WT, BLT1-/-, 
CXCR3-/- and BLT1-/-CXCR3-/- recipient mice were immunized s.c. with 50 
μg/mice of Trp-2 peptide and an adjuvant i.e. 100 μg/mice anti-OX-40 agonistic 
Ab (Clone OX-86, BioXcell). 7 days later, C57BL/6 splenocytes were divided into 
CFSEhigh and CFSElow populations by staining with 2.5 μM and 0.25 μM CFSE 




at 37°C in a 5% CO2 incubator. CFSE high and low cells were extensively 
washed and mixed at 1:1 ratio and injected i.v. into the immunized WT, BLT1-/-, 
CXCR3-/- mice. Their spleens were harvested after two days and analyzed by 
flow cytometry to determine the ratio of CFSEhigh/CFSElow target cells and 
percent killing. The percentage of in vivo killing was calculated by the following 
formula:  
[1 – ([CFSEhigh/CFSElow for experimental]/[CFSEhigh/CFSElow for naive])] × 100.  
Purification of CD8+ T Cells  
CD8+ T cells were isolated from spleen and tumor draining lymph nodes of tumor 
bearing (3-4mm tumor diameter) WT, BLT1-/-, CXCR3-/- or BLT1-/-CXCR3-/- 
double knockout mice using cell sorting using magnetic beads for CD8 (MACS, 
Miltenyi Biotec). In co-transfer experiments, tumor bearing UBC-GFP mice were 
used to obtain CD8+ T cells instead of WT mice.  Briefly, spleen or lymph nodes 
were crushed and passed through 70 μm strainer (Corning). The red blood cells 
were lysed with RBC lysis buffer (Biolegend). After lysis step, cells were 
resuspended in Automax buffer (Miltenyi Biotec) containing 0.5% FBS and 
incubated with CD8+a (Ly-2) micro beads (Miltenyi Biotec). The CD8+ T cells 
were isolated as described by the manufacturers protocol and were positively 
selected on MACS MS columns. The purified CD8+ T cells were > 98% pure as 






Adoptive transfer studies in Rag2-/- mice:  
Rag2-/- immune-deficient mice were challenged s.c. with 105 live B16 cells. Two 
days later, CD8+ T cells were isolated from the spleen and TdLN of tumor 
bearing WT, BLT1-/-, CXCR3-/- or BLT1-/-CXCR3-/- mice by magnetic sorting using 
CD8a-Ly2 microbeads (Miltenyi Biotec) with >98% purity. 1 million purified CD8+ 
T cells were injected i.v. into the Rag2-/- mice challenged with live B16 tumors 
and vehicle alone i.e. PBS was used as the control. Tumor growth was monitored 
every alternate day. Animals were euthanized once they reached 15mm tumor 
diameter and TdLNs as well as tumors were analyzed for CD8+ T cell numbers. 
For, co-transfer experiments, UBC-GFP mice were used as WT mice in order to 
distinguish between WT and knockout (non-GFP) CD8+ T cells. Rag2-/- mice 
were challenged with 105 live B16 cells. Two days later, CD8+ T cells were 
isolated from tumor bearing WT (UBC-GFP), BLT1-/-, CXCR3-/- and BLT1-/-
CXCR3-/- mice. 1 million total CD8+ T cells consisting of WT (GFP+) and either 
BLT1-/-, CXCR3-/- or BLT1-/-CXCR3-/- CD8+ T cells were injected into Rag2-/- mice 
in equal proportion and tumor growth was monitored. Animals were euthanized 
once they reached 7-9mm diameter. Spleen, blood, TdLN and tumors were 









Statistical analysis was done using the Student t test and Mann Whitney U test. 
The survival assays were analyzed using long-rank test in Graph Pad Prism 
software. Student’s t-test were used for comparisons between two experimental 
groups, with a p value of <0.05 considered as significant using Graph Pad Prism 



















BLT1 AND CXCR3 REGULATE ANTI-TUMOR IMMUNITY BY FACILITATING 
CD8+ T CELL MIGRATION TO TUMORS 
 
INTRODUCTION 
Chemokine-chemokine receptor pathways are one of the major factors governing 
CTL recruitment to tumors and anti-tumor immunity [40, 75]. Till date only a few 
chemokine receptor systems are known to regulate T cell homing to tumors and 
anti-tumor immunity. Herein, we studied the roles of leukotriene B4 receptor 
BLT1 and CXCR3 in regulating an endogenous anti-tumor immune response 
using a syngeneic murine model of B16 melanoma. We hypothesize that BLT1-
/- mice would demonstrate defective immune-surveillance and anti-tumor 
immunity against melanoma tumor, as seen in TC-1 cancer. We also 
hypothesize that tumors in CXCR3-/- mice would rapidly develop compared 
to WT mice. Experiments involved challenging WT, BLT1-/- and CXCR3-/- mice 
with B16 melanoma cells subcutaneously. Experiments such as assessing tumor 
infiltrating leukocytes and adoptive transfer of WT or knockout CD8+ T cell in 
tumor bearing Rag2-/- mice were carried out to further investigate the importance 




tumor immunity. Adoptive transfer of either WT, BLT1-/- or CXCR3-/-  tumor 
educated CD8+ T cells in Rag2-/- mice somewhat recapitulates the ACT 
procedure employed in clinic post chemotherapy mediated immune ablation. The 
effector functions of WT and knockout CTLs in periphery as well as in tumors 
were then assessed to understand if apart from migration, the effector functions 
of the T cells are regulated by BLT1 and CXCR3. This is of relevance, since 
previous studies have indicated a co-stimulatory role for chemokine receptors on 
















Defective immune surveillance and anti-tumor immunity in BLT1-/- and 
CXCR3-/- mice: 
Data presented in the previous chapter demonstrated a crucial role for BLT1 in 
CD8+ T cell migration to tumors and anti-tumor immunity in a viral antigen 
derived TC-1 cervical cancer model. To determine the requirement for BLT1 and 
CXCR3 in mediating anti-tumor immunity in an autologous (non-viral) tumor 
model, syngeneic spontaneous B16 melanoma murine model was employed. 
WT, BLT1-/- and CXCR3-/- mice were subcutaneously challenged with either a 
lethal tumor dose (105 cells) or sub-lethal tumor dose (4 x 104 cells) of B16 cells.  
BLT1-/- and CXCR3-/- mice showed significantly enhanced tumor growth as 
compared to the WT mice at both doses of tumor challenge (Figure 9A and 9B) 
and significantly reduced survival as compared to the WT mice at the sub-lethal 
dose (Figure 9C). At the sub-lethal tumor dose both BLT1-/- and CXCR3-/- mice 
demonstrated 100% mortality by day 28 post tumor challenge, however, 50% of 
the WT mice still survived post day 40 with all of them developing relatively slow 
growing tumors (Figure 9C). These results suggest that both BLT1 and CXCR3 
are crucial for immune surveillance and endogenous anti-tumor response.  There 
was no difference between the tumor kinetics of BLT1-/- and CXCR3-/- mice at  
both lethal and sub-lethal tumor doses, suggesting that they both are crucial to 






Reduced homing of CD8+ T cells into tumors of BLT1-/- and CXCR3-/- mice 
To explore the basis for enhanced tumor growth in the knockout mice, leukocyte 
sub-populations in tumors, spleen and TdLN of tumor bearing WT, BLT1-/- and 
CXCR3-/- mice were profiled by flow cytometry. WT, BLT1-/- and CXCR3-/- mice 
were challenged with 105 B16 cells and the tumors were harvested when the 
knockout tumors reach 7-9 mm (mid-sized) tumor diameter. Single cell 
suspensions were obtained from the tumor, spleen and TdLN and stained with 
CD45.2 for all immune cell populations and CD3, CD4 and CD8 for T cells, 
NK1.1 for NK cells, CD11b, Ly6G and Ly6C for myeloid cell populations. The 
BLT1-/- and CXCR3-/- tumors showed significant reduction in CD8+ T cell numbers 
as compared to WT tumors (Figure 10A). Moreover, CXCR3-/- tumors, but not 
BLT1-/- tumors, had significant reduction in other effector cell populations like 
CD4+ T cell and NK cells as compared to the WT tumors. To ensure that reduced 
CTL numbers are not a function of differential tumor sizes, TIL infiltration, studies 
were carried out in size-matched tumors. Similar reduction in CD8+ T cell 
numbers in tumors of knockout mice as compared to WT mice was observed at 
size matched (end stage) tumors as well (Figure 10B). The significant reduction 
in CD8+ T cells in the tumors of BLT1-/- and CXCR3-/- mice was confirmed by 
immune-fluorescence staining and confocal microscopy (Figure 10C). Immune 
cell profiling in the spleen (Figure 11) and TdLN (Figure 12) revealed that 
knockout mice had similar percentages of CD8+ T cells, CD4+ T cells and NK 
cells as compared to WT mice. Myeloid cell populations constitute a significant 




myeloid derived suppressive cells subsets (MDSC) i.e. CD11b+Ly6G+ 
(granulocytic-MDSC) and CD11b+Ly6C+ (monocytic - MDSC) in the tumors of 
WT, BLT1-/- and CXCR3-/- mice showed no significant differences (Figure 13). 
These results suggest that enhanced tumor growth in BLT1-/- and CXCR3-/- mice 
may be related to the reduced numbers of cytotoxic cells as compared to tumors 
of WT mice.  
Effector responses in WT, BLT1-/- and CXCR3-/- mice 
To assess the effector responses controlled by BLT1 and CXCR3, transcript 
expression of various effector molecules and IFNγ regulated genes were 
analyzed in total tumor RNA of WT, BLT1-/- and CXCR3-/- mice by quantitative 
real time PCR as described in methods. Transcript expression levels of CTL 
effector molecules like granzyme-B and IFNγ were significantly reduced in 
tumors of BLT1-/- and CXCR3-/- mice as compared to WT mice as shown by RT-
PCR (Figure 14 A and 14 B). Expression of interferon gamma inducible genes 
like CXCL9 and CXCL10 were also determined. CXCL9, ligand for CXCR3 
induced by IFNγ was significantly reduced in tumors of both BLT1-/- and CXCR3-/- 
mice while CXCL10, another ligand for CXCR3 was significantly reduced in 
CXCR3-/- mice (Figure 14 C and 14D). Significantly less IFNγ, Granzyme-b and 
interferon gamma inducible chemokines CXCL9 and CXCL10 in CXCR3-/- mice 
precludes the infiltration of T cells and NK cells that are major producers of IL-2 
and IFNγ. CXCR3-/- tumors showed significantly reduced IL-2 and prevents the 
feed-forward loop of T cell infiltration>IFNγ>CXCL9/10>T cell infiltration and 




show reduced NK cells and CD4+ T cells that are major These results suggest 
defective effector responses in tumors of BLT1-/- and CXCR3-/- mice compared to 
WT mice reflective of reduction in CTL numbers to tumors. 
Effector responses of WT, BLT1-/- and CXCR3-/- CD8+ T cells 
In order to understand if BLT1 and CXCR3 receptors contribute to effector 
functions in the CD8+ T cellS; IFNγ and TNFα effector cytokines were analyzed in 
tumor infiltrated CD8+ T cells as well as CD8+ T cells from spleen and TdLN of 
tumor bearing mice. Invivo cytotoxicity assay was also performed to examine the 
cytotoxic ability of WT and knockout CD8+ T cells in the spleens of immunized 
WT and knockout mice. 
 To assess whether the function of CD8+ T cells in BLT1-/- and CXCR3-/- is intact 
or defective, we assessed the in vivo killing activity of CD8+ T cells in WT, BLT1-/- 
and CXCR3-/- mice. Briefly, WT, BLT1-/- and CXCR3-/- recipient mice were 
immunized s.c. with 50μg/mice of Trp-2 peptide and an adjuvant i.e. 100μg/mice 
anti-OX-40 agonistic Ab (Clone OX-86, BioXcell). 7 days later, C57BL/6 
splenocytes were divided into CFSEhigh and CFSElow populations by staining with 
2.5μM and 0.25μM CFSE fluorescent dye. CFSEhigh cells were pulsed with 
2μg/ml Trp-2 peptide. CFSE high and low cells were extensively washed and 
mixed at 1:1 ratio and injected i.v. into the immunized and naïve WT, BLT1-/- and 
CXCR3-/- mice. Their spleens were harvested after two days and analyzed by 
flow cytometry to determine the ratio of CFSEhigh/CFSElow target cells and 




as well as BLT1-/- and CXCR3-/- CD8+ T cells (Figure 15 A-D). These results 
suggest that there is no intrinsic defect in the cytotoxic function of the knockout 
CD8+ T cells in the periphery. However, in the tumor microenvironment, the lack 
of CXCR3 receptor on the CD8+ T cells may render them defective in terms of 
IFNγ production and effector functions.  
Given that BLT1 and CXCR3 are essential for homing into tumors, we sought to 
determine if the effector functions were also controlled by BLT1 and CXCR3. To 
measure their cytotoxic function within the tumor, levels of IFNγ, an effector 
cytokine was determined in the CD8+ T cells by intracellular cytokine staining. 
The percent IFNγ+ cells of total CD8+ T cells in the tumors of CXCR3-/- mice was 
significantly reduced as compared to WT mice; but remained similar in the 
tumors of BLT1-/- mice (Figure 16A). In contrast, percent IFNγ+ cells of total 
CD8+ T cells in spleens and TdLNs of tumor bearing WT, BLT1-/- and CXCR3-/- 
mice were similar. Interestingly, CXCR3-/- CD8+ T cells showed intact TNFα 
production in the tumor as also in spleen and TdLN (Figure 16B). 
 
Adoptively transferred WT but not BLT1-/- or CXCR3-/- CD8+ T cells delayed 
tumor growth in Rag2-/- mice 
To further examine the importance of BLT1 and CXCR3 expression on CD8+ T 
cells for effective infiltration to tumors, adoptive transfer model involving Rag2-/- 
mice was employed. Rag2-/- mice have intact innate systems and hence allow us 




function in anti-tumor immunity. Rag2-/- mice were challenged with 105 B16 cells 
and 2 days later were adoptively transferred with tumor educated sorted (>98% 
pure) WT or BLT1-/- CD8+ T cells and the tumor growth was recorded. PBS 
transferred tumor bearing Rag2-/- mice served as controls. WT CD8+ T cells 
significantly reduced the tumor progression in Rag2-/- animals.  However, BLT1-/- 
CD8+ T cells failed to retard the tumor growth and showed tumor growth kinetics 
similar to control Rag2-/- mice without any transferred CD8+ T cells; reinforcing 
the crucial role of BL1 in anti-tumor immunity (Figure 17A). CTL infiltration 
studies showed that BLT1-/- CTLs were significantly reduced in tumors of Rag2-/- 
mice as compared to WT CTLs. Analysis of CD8+ T cells in TdLN revealed no 
difference in homeostatic proliferation and numbers between transferred WT and   
BLT1-/- CD8+ T cells (Figure 17B). This suggests a defective tumor homing 
ability of BLT1-/- CTLs.  
Similar studies were carried out with WT and CXCR3-/- CTLs. CXCR3-/- CTLs 
also failed to retard tumor growth in Rag2-/- mice suggesting CXCR3 is crucial in 
anti-tumor immunity (Figure 18A). This defective anti-tumor response was 
attributed to significantly reduced levels of CXCR3-/- CTLs in the tumors, their 
levels remaining similar in the TdLN suggesting no difference between the 
proliferation of WT and CXCR3-/- CTLs (Figure 18B). These studies demonstrate 
that expression of both BLT1 and CXCR3 on CTLs is necessary for their effective 








Figure 9: Enhanced tumor growth and reduced survival in BLT1-/- and 
CXCR3-/- mice. A, WT, BLT1-/- and CXCR3-/- mice were challenged 
subcutaneously with 105 B16 cells (lethal dose). Tumor area was determined by 
multiplication of two perpendicular diameters (LxW). n=9 for each group. B, WT 
(n=10), BLT1-/- (n=7) and CXCR3-/- (n=8) mice were challenged subcutaneously 
with 4x104 B16 cells (sub-lethal dose) and the tumor area calculated. C, Survival 















































































































































































challenge. Log-rank test and Kaplan-Meier methods were used for survival 
analyses and student t tests were used for tumor sizes. A, Data is representative 








Figure 10: Reduced infiltration of CD8+ T cells in BLT1-/- and CXCR3-/- 
tumors.  A) Reduced CD8+ T cells in tumors of knockout mice at mid-sized 
tumor, day matched. Numbers of tumor infiltrating CD8+ T cells, CD4+ T cells 
and NK1.1+ cells per million total tumor cells (frequency of total) were analyzed 
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described in Methods. All the mice were sacrificed and tumors harvested when 
the knockout tumors reached 7-9mm tumor diameter (mid-sized). B) Reduced 
CD8+ T cells in size-matched end staged tumors of knockout mice. Numbers 
of tumor infiltrating CD8+ T cells, CD4+ T cells and NK1.1+ cells per million total 
tumor cells (frequency of total) were analyzed from WT, BLT1-/- and CXCR3-/- 
mice using standard flow cytometry protocol as described in Methods. All tumors 
were analyzed at large end staged (15 mm tumor diameter), size matched 
tumors. n=4 in each group. C) Representative immunofluorescence staining 
images of CD8+ T cells in WT, BLT1-/- and CXCR3-/- tumors. Tumors 
harvested were frozen, sectioned and stained as described in Methods, CD8 
represented in Red, DAPI in blue. The images were captured using Nikon A1R 











Figure 11: Similar numbers of CD8+ T cells in spleens of WT, BLT1-/- and 
CXCR3-/- tumor bearing mice: Spleens were harvested, processed into single 
suspension, stained for CD3, CD8, CD4 and NK1.1 markers and analyzed via 
flow cytometry as mentioned in the methods. CD8+ T cells, CD4+ T cells, NK1.1+ 
cells in spleen of size-matched, end staged (14-15mm tumor diameter) tumor 
bearing WT, BLT1-/- and   CXCR3-/- mice. Cells represented as percent of total 
CD45+ cells (A) as well as absolute numbers represented as frequency of total 



























































































































































































































Figure 12: Similar numbers of CD8+ T cells in TdLNs of WT, BLT1-/- and 
CXCR3-/- tumor bearing mice: Tumor draining lymph nodes (TdLN- inguinal, 
brachial and axillary) were harvested, processed into single suspension, stained 
for CD3, CD8, CD4 and NK1.1 markers and analyzed via flow cytometry as 
mentioned in the methods. CD8+ T cells, CD4+ T cells, NK1.1+ cells in TdLN of 
size-matched, end staged (14-15mm tumor diameter) tumor bearing WT, BLT1-/- 
and   CXCR3-/- mice. Cells represented as percent of total CD45+ cells (A) as 
well as absolute numbers represented as frequency of total lymph node cells (B). 


































































































































































Figure 13: Similar numbers of of myeloid cell subsets in tumors of WT, 





) subsets per million total tumor cells (frequency of total) 
were analyzed from size matched, end staged (14-15 mm tumor diameter) WT, 
BLT1-/- and CXCR3-/- mice using standard flow cytometry protocol as described in 




































































































































Figure 14: Effector responses in tumors of WT, BLT1-/- and CXCR3-/- mice. 
Quantitative real time PCR of effector molecules and interferon gamma regulated 
genes. The levels of Granzyme-B (A), IFNγ (B), CXCL9 (C) and CXCL10 (D) 
mRNA expression in tumors from WT, BLT1-/- and CXCR3-/- mice were 
determined by RT-PCR as described in methods. Expression of the target genes 
was normalized to GAPDH. Data displayed as fold change relative to the WT 




















































































































































































































































































             
Figure 15: BLT1-/- and CXCR3-/- CD8+ T cells display normal cytotoxic 
function in the spleen. The CD8+ T cell based In vivo killing assay was 
performed as described in the Methods. WT, BLT1-/- and CXCR3-/- recipient mice 
were immunized s.c. with 50 μg/mice of Trp-2 peptide and an adjuvant i.e. 100 
μg/mice anti-OX-40 agonistic Ab (Clone OX-86, BioXcell). Naïve WT, BLT1-/- and 
CXCR3-/- mice were used as controls. Representative histograms of CFSE-
labeled targets viz. CFSE hi and CFSE low determining the killing in A) 
Immunized WT mice, B) Immunized BLT1-/- mice and C) Immunized CXCR3-/- 
mice. D) Cumulative levels of percent killing activity by respective CTLs are 
shown as a bar graph. n=4 in each group.  






























Figure 16: Effector functions of WT, BLT1-/- and CXCR3-/- CD8+ T cells in 
periphery versus tumor. A) Intracellular IFNγ staining was performed in WT, 
BLT1-/- and   CXCR3-/- total tumor cell suspension by ex-vivo stimulation in the 
presence of PMA and ionomycin as mentioned in the methods. Percent IFNγ+ 
cells of total CD8+ T cells were analyzed in tumors (mid-sized tumors). CXCR3-/- 
CD8+ T cells in periphery have intact IFNγ secretion. Percent IFNγ+ cells of total 
CD8+ T cells were analyzed in TdLNs and spleens of tumor bearing WT, BLT1-/- 
and CXCR3-/- mice (mid-sized tumor). Data is representative of two independent 
experiments with n=4 animals in each group. B) Intracellular TNFα staining was 
performed in WT, BLT1-/- and CXCR3-/- total tumor cell suspension by ex-vivo 
stimulation in the presence of PMA and ionomycin as mentioned in the methods. 


































































































































































































spleens of tumor bearing WT and CXCR3-/- mice (mid-sized tumor). Data is 
representative of two independent experiments with n=4 animals in each group. 
 


































                 
Figure 17: Adoptive transfer of WT but not BLT1-/- tumor experienced CD8+ 
T cells retarded tumor growth in Rag2-/- mice. Rag2-/- mice were challenged 
with 105 B16 cells. Two days later CD8+ T cells were isolated from the spleen 
and TdLN of B16 tumor bearing (3-5mm) WT or BLT1-/- mice by MACS technique 
and 1 million isolated CD8+ T cells  (>98% purity) or PBS were injected i.v. in 
tumor inoculated Rag2-/- mice. A, Tumor growth kinetics for Rag2-/- mice 




























































































































































(n=5). B, Numbers of CD8+ T cells (frequency of total) per million total tumor cells 
and percent CD8+ T cells of total CD45+ cells in TdLN for WT and BLT1-/- 
transferred CD8+ T cells are shown as cumulative bar graphs. Data is 









                
Figure 18: Adoptive transfer of WT but not CXCR3-/- tumor experienced 
CD8+ T cells retarded tumor growth in Rag2-/- mice. Rag2-/- mice were 
challenged with 105 B16 cells. Two days later CD8+ T cells were isolated from the 
spleen and TdLN of B16 tumor bearing (3-5mm) WT or CXCR3-/- mice by MACS 
technique and 1 million isolated CD8+ T cells  (>98% purity) or PBS were injected 
i.v. in tumor inoculated Rag2-/- mice. A, Tumor growth kinetics for Rag2-/- mice 






























































































































cells (n=5). B, Numbers of CD8+ T cells (frequency of total) per million total tumor 
cells and percent CD8+ T cells of total CD45+ cells in TdLN for WT and CXCR3-/- 
transferred CD8+ T cells are shown as cumulative bar graphs. Data is 





















LACK OF BLT1 AND CXCR3 MEDIATED SYNERGISM TO FACILITATE CTL 
MIGRATION TO TUMORS AND ANTI-TUMOR IMMUNITY 
 
INTRODUCTION 
The data presented in the previous chapter indicated the individual importance of 
BLT1 and CXCR3 in regulating CTL migration to tumors and thus anti-tumor 
immunity. The data indicated that both BLT1 and CXCR3 deficient mice had 
similar significantly enhanced tumor growth kinetics, compared to WT mice. In 
this chapter we sought to investigate whether BLT1 and CXCR3 receptor 
mediated T cell homing acts in concert or is synergistic in function. For this 
purpose, BLT1-/-CXCR3-/- double deficient mouse was generated by crossing 
BLT1-/- mouse to CXCR3-/- mouse.  
Tumor growth in double knockout mice was compared to either of the single 
knockout to infer whether synergism exist with respect to regulation of anti-tumor 
immunity as well as CD8+ T cell migration to tumors. We hypothesize that BLT1 
and CXCR3 mediated regulation of CD8+ T cell migration to tumors and 
anti-tumor immunity acts in concert. We expect to see a further enhancement 




Also, the interdependence of BLT1 and CXCR3 mediated regulation of CTL 
migration to tumors was examined by employing co-transfer strategies of WT 
CD8+ T cells with either of the knockout cells (BLT1-/-, CXCR3-/- or BLT1-/-
CXCR3-/- CD8+ T cells) in equal proportion in the adoptive transfer model 
employed in previous experiments. WT CTLs facilitating either of BLT1-/- or 
CXCR3-/- CD8+T cell infiltration but not BLT1-/-CXCR3-/- CD8+ T cells to tumors 
would mean a possible interdependence between BLT1 and CXCR3 pathways. 
We hypothesize that WT CD8+ T cells could facilitate additional BLT1 
deficient CD8+ T cells via CXCR3 receptor. This hypothesis stems from 
previously published study where BLT1 mediated infiltration of WT neutrophils in 
BLT1-/- mice facilitated infiltration of endogenous BLT1-/- neutrophils to the 
inflamed joint suggesting that BLT1 expression on neutrophils is essential only 
for the initial recruitment and other chemokines could then perpetuate the 
disease progression [180]. We expect that the initial infiltration of WT CTLs to 
tumors would enable IFN > CXCL9/10 > CXCR3 mediated T cell homing loop, to 
enhance the infiltration of additional BLT1-/- CTLs via CXCR3 receptor. 
These experiments would provide us the plausible combinatorial regulatory 
mechanisms for BLT1 and CXCR3 mediated T cell homing to tumors as well as 










Generation of BLT1-/-CXCR3-/- mice 
BLT1 receptor gene, Ltb4R, is localized to chromosome 14 in mice as well as in 
humans (autosomal) [179]. On the other hand, CXCR3 gene Cxcr3 is located on 
the sex-chromosome and is an X-linked gene both in mice and humans [133]. 
Hence, males are hemizygous for CXCR3 gene and females are homozygous. 
BLT1-/- female mice were bred with CXCR3-/- male mice to generate BLT1-
CXCR3 heterozygous female mice. BLT1-CXCR3 heterozygous females were 
then bred with BLT1-/- males to generate BLT1-/-CXCR3+/- females and BLT1-/-
CXCR3-/- males. The BLT1-/-CXCR3+/- females were then bred with BLT1-/-
CXCR3-/- males to generate BLT1-/-CXCR3-/- female mice. The BLT1-/-CXCR3-/- 
male and female mice were then bred with each other for several rounds of 
breeding to generate BLT1-/-CXCR3-/- male and female breeders. The 
representative breeding scheme is shown in Table 1. The BLT1-/-CXCR3-/- mice 
were born at the expected Mendelian ratios and displayed normal developmental 
and morphological features. 
Accelerated tumor growth and reduced survival in BLT1-/-CXCR3-/- mice 
To examine the interdependence of BLT1 and CXCR3 receptor mediated 
regulation in anti-tumor immunity, BLT1-/-CXCR3-/- double knockout mouse 
(DKO) was generated as discussed. At the sub-lethal dose of B16 cells (4x104), 




significantly reduced survival as compared to WT mice (Figure 19 A and B). 
There was 100% mortality of BLT1-/-CXCR3-/- mice by day 22, while 50% of WT 
mice still survived at day 35-post tumor challenge (Figure 19B).  
 To compare the tumor growth kinetics in double knockout mice versus either of 
the single knockout mice; WT, BLT1-/-, CXCR3-/- and BLT1-/-CXCR3-/- mice were 
challenged with 105 B16 cells followed by tumor growth kinetic analysis. The 
BLT1-/-CXCR3-/- mice displayed significantly enhanced tumor growth kinetics as 
compared to WT mice but similar growth kinetics as compared to BLT1-/- or 
CXCR3-/- mice at lethal tumor dose (Figure 20A). No significant difference was 
observed in the survival (Figure 20B) or the tumor growth (data not shown) 
between either of the single knockout mice and double knockout mice even at 
the sub-lethal dose. Therefore, these results suggest that BLT1 and CXCR3 
mediated regulation of anti-tumor immunity may be co-dependent but not additive 
or synergistic.  
 
WT CTLs do not facilitate knockout CTL infiltration to tumors 
The migration patterns of the WT and knockout CD8+ T cells co-transferred into 
Rag2-/- mice were determined to explore whether WT CTLs can facilitate the 
trafficking of knockout CTLs into tumors. Equal proportions of tumor experienced 
WT CD8+ T cells and BLT1-/-, CXCR3-/- or BLT1-/-CXCR3-/- (DKO) CD8+ T cells 
were introduced intravenously in tumor bearing Rag2-/- mice. UBC-GFP mice 
were used as WT mice to differentiate between WT (bright green fluorescence) 




blood, spleen and TdLN once the tumor reached 7-9 mm diameter and the ratio 
of WT to knockout CD8+ T cells was assessed. The ratios of WT to knockout 
CTLs in TdLN were similar across all the groups and close to 1-1.5 (Figure 22). 
WT CD8+ T cells infiltrated into tumors around 3 fold more as compared to BLT1-
/- CD8+ T cells, around 8 fold more as compared to CXCR3-/- CD8+ T cells and 
around 5.5 fold more as compared to BLT1-/-CXCR3-/- CD8+ T cells (Figure 23). 
In contrast, the numbers of BLT1-/-, CXCR3-/-, and BLT1-/-CXCR3-/- CD8+ T cells 
were 1.5 to 3 fold higher than the WT cells in the blood and spleen (Figure 24). 
These studies suggest that WT cells do not facilitate additional knockout CTL 
















Table 1: Breeding scheme for generation of BLT1-/-CXCR3-/- mice: Breeding 
scheme to generate BLT1-/-CXCR3-/- double deficient mice. BLT1-/- females were 
bred with CXCR3-/- males to generate BLT1-CXCR3 heterozygous females. 
BLT1-CXCR3 heterozygous females were then bred with BLT1-/- males to 
generate BLT1-/-CXCR3+/- females and BLT1-/-CXCR3-/- males. The BLT1-/-
CXCR3+/- females were then bred with BLT1-/-CXCR3-/- males to generate BLT1-/-
CXCR3-/- females. The BLT1-/-CXCR3-/- males and females were then bred with 
each other for several rounds of breeding to generate BLT1-/-CXCR3-/- male and 
female breeders. The representative breeding scheme is shown. 
Cross Parent (Male) Parent (Female)       Selected Progeny 
1. CXCR3-/- BLT1-/- BLT1+/- CXCR3+/- Female 
 
2.  BLT1-/- BLT1+/- CXCR3+/-  a) BLT1-/-CXCR3-/-  Male 
  
b) BLT1-/- CXCR3+/- Female 
 
3.  BLT1-/-CXCR3-/-  BLT1-/- CXCR3+/-  a) BLT1-/-CXCR3-/-  Male 
 
b) BLT1-/-CXCR3-/-  Female 
4. BLT1-/-CXCR3-/-  BLT1-/-CXCR3-/-  BLT1-/-CXCR3-/-  male and 





Figure 19: Defective immune surveillance and anti-tumor immunity in BLT1-
/-CXCR3-/- double knockout (DKO) mice. A, WT (n=10) and BLT1-/-CXCR3-/- 
(n=6) mice were challenged subcutaneously with 4x104 B16 cells (sub-lethal 
dose) and the tumor area calculated. Tumor area was measured by multiplication 
of two perpendicular diameters (LxW). B, Survival in mice with sub-lethal dose of 
tumor challenge was monitored till day 35 post tumor challenge. Log-rank test 
and Kaplan-Meier methods were used for survival analyses and student t tests 










































Figure 20: Lack of synergism in BLT1 and CXCR3 mediated regulation in anti-
tumor immunity. A) WT (n=4), BLT1-/- (n=5), CXCR3-/- (n=4) and BLT1-/-CXCR3-/- (n=6) 
mice were challenged subcutaneously with 105 B16 cells (lethal dose). Tumor area was 
measured by multiplication of two perpendicular diameters (LxW). B) WT (n=10), BLT1-
/- (n=7), CXCR3-/- (n=7) and BLT1-/-CXCR3-/- (n=6) mice were challenged 
subcutaneously with 4x104 B16 cells (sub-lethal dose). Survival in mice with sub-
lethal dose of tumor challenge was monitored till day 40 post tumor challenge 
Data is representative of two independent experiments. Log-rank test and Kaplan-











         
Figure 21: Equal proportions of WT (GFP) and knockout CD8+ T cells 
adoptively transferred in tumor bearing Rag2-/- mice. Co-transfer experiments 
were performed as mentioned in methods. Briefly, CD8+ T cells were isolated 
from tumor bearing (3-5 mm) WT (GFP), BLT1-/- (non-GFP), CXCR3-/- (non-GFP) 
mice and BLT1-/-CXCR3-/- (non-GFP) mice. WT and KO CD8+ T cells were 


































Representative dot plots of GFP+ (WT) and GFP- (KO) CTLs transferred in tumor 
inoculated Rag2-/- mice and corresponding cumulative bar graph of ratio of %WT 
to %KO CD8+ T cells (gated on CD3+CD8+ cells) injected which is equal to 1. Bar 
in black represents WT + BLT1-/- CTL mix; grey bars represent WT + CXCR3-/- 
CTL mix and light grey bar represents WT + DKO CTL mix. Data is 
representative of two independent experiments.  













Figure 22: Equal proportions of WT and knockout CD8+ T cells in the TdLN 
of Rag2-/- mice. Co-transfer experiments were performed as mentioned in 
methods. Briefly, CD8+ T cells were isolated from tumor bearing (3-5mm) 
WT(GFP), BLT1-/- (non GFP), CXCR3-/- (non-GFP) mice and BLT1-/-CXCR3-/- 
(non-GFP) mice. WT and KO CD8+ T cells were equally mixed and 1 million cells 
were injected i.v. in tumor bearing Rag2-/- mice.  Animals were sacrificed when 
the tumors reached 7-8mm tumor diameter. %WT and KO CD8+ T cells were 
determined upon gating on live CD3+CD8+ T cells and looking for GFP+ and GFP- 






































obtained from TdLNs of Rag2-/- mice when the tumor reaches 7-8mm tumor 
diameter. Cumulative bar graph demonstrating the ratio of %WT to %KO CTLs in 
TdLN is also shown. Data is representative of two independent experiments for 















Figure 23: WT CD8+ T cells do not facilitate knockout CD8+ T cell infiltration 
to tumors. Co-transfer experiments were performed as mentioned in methods. 
A) Representative dot plots of %WT and %KO CTLs obtained from tumor of 
Rag2-/- mice when the tumor reaches 7-8mm tumor diameter. The %GFP+ and 
%GFP- is shown after gating on CD8+ T cells. B) Cumulative bar graph 
demonstrating the ratio of %WT to %KO CTLs in TdLN is also shown. C) 
Cumulative bar graph demonstrating total live CD8+ T cells in tumors of Rag2-/- 
mice adoptively transferred with equal proportions of WT and knockout CD8+ T 


































CXCR3-/- CTL mix and light grey bar represents WT + DKO CTL mix. Data is 
representative of two independent experiments for each transferred combination 


















Figure 24: CXCR3-/- and DKO CD8+ T cells are significantly more as 
compared to WT cells in blood and spleen of tumor bearing Rag2-/- mice. 
Co-transfer experiments were performed as mentioned in methods. Briefly, CD8+ 
T cells were isolated from tumor bearing (3-5mm) WT(GFP), BLT1-/- (non GFP), 
CXCR3-/- (non-GFP) mice and BLT1-/-CXCR3-/- (non-GFP) mice. WT and KO 
CD8+ T cells were equally mixed and 1 million cells were injected i.v. in tumor 
bearing Rag2-/- mice.  Animals were sacrificed when the tumors reached 7-8mm 
tumor diameter. %WT and KO CD8+ T cells were determined upon gating on live 
CD3+CD8+ T cells and looking for GFP+ and GFP- populations respectively. 
Cumulative bar graph representing ratio of %WT to %KO CTLs (frequency of 
CD8+ T cells) is shown. Data representative of two independent experiments with 






























































































































































Data from previous chapters demonstrated the role of BLT1 and CXCR3 receptor 
in regulating endogenous anti-tumor responses. In this chapter we sought to 
investigate the role of BLT1 and CXCR3 receptors in regulating a vaccine-
induced immune response. Whether BLT1 and CXCR3 receptor mediated CTL 
recruitment to tumors and anti-tumor immunity could be bypassed under the 
presence of an external immune stimulation was tested. We tested PD-1 
blockade based immunotherapy to answer this question.  
PD-1 is an immunosuppressive molecule present on T cells that have been 
activated against an antigen. PD-1 based immunosuppression is involved in 
restraining or attenuating an inflammatory response after an infection or cause 
for inflammation has been eliminated. However, in the context of anti-tumor 
immunity, as discussed before, PD-L1-PD-1 based immunosuppression leads to 
tumor mediated immunosuppression of CTLs enabling tumor immune evasion. 
Blocking PD-1 expression on T cells enhances anti-tumor immunity and has 




In order to conduct this experiment, we employed PD-1 antagonistic antibody 
based vaccine formulation consisting of Trp-2 melanoma peptide. The vaccine 
was administered as a therapeutic regimen upon tumor challenge. The data 
presented here indicate an obligate requirement for BLT1 and CXCR3 receptors 
in obtaining vaccine efficacy. CTL infiltration studies were carried out in tumors, 
spleen, TdLN and blood of unvaccinated and vaccinated mice. This chapter 
would provide essential information on the requirement of BLT1 and CXCR3 





















Obligate requirement for BLT1 and CXCR3 in anti-PD-1 Ab based vaccine 
efficacy  
The importance of BLT1 and CXCR3 in vaccine induced anti-tumor immune 
response was determined. WT, BLT1-/-, CXCR3-/- and BLT1-/-CXCR3-/- mice were 
challenged with 105 B16 cells subcutaneously on Day 0 followed by vaccine 
administration on day +5 and day +15. Although the vaccine did not completely 
eradicate the tumors in WT mice, there was a significant reduction in the tumor 
growth kinetics in WT mice upon vaccination. However, the vaccine completely 
failed to delay tumor growth in the BLT1-/-, CXCR3-/- and BLT1-/-CXCR3-/- animals 
(Figure 25).  
The vaccine efficacy correlated with CD8+ T cell infiltration to tumors, with 
significantly reduced CD8+ T cell infiltration in tumors of knockout mice upon 
vaccination. As expected the vaccine decreased CD8+ T cell numbers in the 
blood of WT mice as a reflection of the concurrent increase in the CD8+ T cells in 
tumors of WT mice (Figure 26). The percentages of CD8+ T cells in the TdLNs 
and spleens of the knockout animals were comparable to the WT animals in both 
the vaccinated and unvaccinated cohorts (Figure 27). The ability of the vaccine 
to enhance CD8+ T cell migration in WT tumors but not the knockout tumors was 
also confirmed by confocal microscopy (Figure 27 A). Granzyme-B an effector 
molecule secreted by CD8+ T cells was significantly enhanced in WT mice upon 




suggesting reduction in effector responses in tumors of knockout mice with or 
without vaccination (Figure 27 B). CD8+ T cells derived from blood and TdLN of 
tumor bearing mice showed increased BLT1 expression (increased mean 
fluorescent intensity) and a moderate CXCR3 upregulation (more counts of cells 
expressing CXCR3) upon vaccination  (Figure 28A and 28 B). These results 
suggest that optimum efficacy of anti-PD-1 antibody based vaccine requires the 
expression of both BLT1 and CXCR3 for effective CTL infiltration to tumors and 
















Figure 25: Obligate requirement of BLT1 and CXCR3 for optimum efficacy 
of anti-PD-1 antibody based immunotherapy. WT (Unvacc: n=4, Vacc: n=6), 
BLT1-/- (Unvacc: n=5, Vacc: n=5), CXCR3-/- (Unvacc: n=3, Vacc: n=5) and DKO 
(Unvacc: n=6, Vacc: n=5) mice were subcutaneously challenged with 105 B16 




and anti-PD-1 Ab (100 µg) twice intravenously on day +5 and +15 post tumor 
inoculation.  Tumor area measured by multiplication of two perpendicular 
diameters in unvaccinated and vaccinated WT, BLT1-/-, CXCR3-/- and DKO mice 














Figure 26: Vaccine enhances CD8+ T cell infiltration in tumors of WT mice 
but not knockout mice. WT (Unvacc: n=4, Vacc: n=6), BLT1-/- (Unvacc: n=5, 
Vacc: n=5), CXCR3-/- (Unvacc: n=3, Vacc: n=5) and DKO (Unvacc: n=6, Vacc: 
n=5) mice were subcutaneously challenged with 105 B16 cells and left either 
unvaccinated (PBS) or vaccinated with Trp-2 peptide (50 µg) and anti-PD-1 Ab 
(100 µg) twice intravenously on day +5 and +15 post tumor inoculation. A. 
Enhanced CD8+ T cell numbers in tumors of WT mice but not knockout mice 
upon vaccination. Cumulative bar graph representing CD8+ T cell numbers per 








































































































































































































































































































BLT1-/-, CXCR3-/- and DKO mice is represented. B,C. Cumulative bar graph 
representing %CD8+ T cells (frequency of CD45+ cells) in spleen (B) and TdLN 
(C) of unvaccinated and vaccinated WT, BLT1-/-, CXCR3-/- and DKO mice is 
shown. D. Cumulative bar graph representing %CD8+ T cells (frequency of 
CD45+ cells) in blood of unvaccinated and vaccinated WT, BLT1-/-, CXCR3-/- and 




















                          
Figure 27: Vaccine enhances CD8+ T cell infiltration in tumors of WT mice 
but not knockout mice. A) Representative immunofluorescence staining 
images of CD8+ T cells in WT, BLT1-/- and CXCR3-/- tumors from vaccinated or 




































































































described in Methods, CD8 represented in Red, DAPI in blue. The images were 
captured using Nikon A1R confocal microscope. The scale represents 50 µM. 
Data representative of two independent experiments. B) Enhanced CD8+ T cell 
numbers in tumors of WT mice but not knockout mice upon vaccination. 
Cumulative bar graph representing CD8+ T cell numbers per million total tumor 
cells (frequency of total) in unvaccinated and vaccinated WT, BLT1-/-, CXCR3-/- 
and DKO mice is represented. Also, fold change of granzyme-B transcript in RNA 
isolated from WT, BLT1-/- and CXCR3-/- tumors of vaccinated and unvaccinated 
mice when the knockout tumors reach 15mm tumor diameter is shown. GAPDH 
was used as the housekeeping gene. Relative fold change to WT tumors is 











             
 
Figure 28: Enhanced expression of BLT1 and CXCR3 on CD8+ T cells upon 
vaccination. CD8+ T cells from blood and tumor draining lymph nodes of 
unvaccinated and vaccinated tumor bearing WT mice were analyzed for BLT1 
Antibody developed in the lab (unpublished study) and CXCR3 as mentioned in 
the methods section. n=5 in each group. A) Representative histogram plots for 

























TdLN of WT vaccinated and unvaccinated control mice. Dotted line represents 
WT unvaccinated CD8+ T cells and solid black line represents WT vaccinated 
CD8+ T cells. B) Representative histogram plots for CXCR3 expression on CD8+ 
T cells (gated on CD3+CD8+ T cells) from blood and TdLN of WT vaccinated and 
unvaccinated control mice. Dotted line represents WT unvaccinated CD8+ T cells 





















Cancer immunotherapies rely on achieving stronger and long lasting effector 
CD8+ T cell responses in the tumor. A major obstacle for attaining this goal is the 
inefficient migration of CD8+ T cells into the tumor [40, 75, 144]. The results 
presented here suggest that both BLT1 and CXCR3 are independently required 
for CD8+ T cell migration to tumors and sustained anti-tumor immunity. In the 
absence of either of these receptors, there is a breach in achieving an effective 
anti-tumor response.  
Although BLT1 is expressed on a variety of leukocytes, there is a preferential 
BLT1 mediated recruitment of certain cells under specific disease condition. For 
example, Th2 and CD8+ T cells cell infiltration is preferred during airway 
hyperresponsiveness in asthma, T cells in autoimmune uveitis, macrophages in 
diet induced obesity and atherosclerosis and neutrophils in silica induced lung 
cancer promotion; in all of these models genetic deletion of BLT1 was shown to 
be protective [181, 183, 186, 189-192]. Recently, we demonstrated a crucial anti-
tumor role of BLT1 in mediating CD8+ T cell recruitment to tumors using TC-1 
cervical cancer model wherein BLT1 deficient mice showed enhanced tumor 
growth and reduced survival compared to WT mice [176]. Lack of CTL infiltration 




Using an autologous melanoma tumor model expressing self-antigens [193], 
herein we corroborated that BLT1 mediates CTL recruitment to tumors and thus 
plays an important role in anti-tumor immunity; consistent with the TC-1 cervical 
cancer model. This suggests that BLT1 mediated regulation of CTL infiltration 
may be true across a variety of immunogenic solid tumor types. Hence, BLT1 
mediated recruitment of various immune cells at specific locations in different 
tumor models is key to the type of inflammation (pro-tumor or anti-tumor) that 
accrues.  In melanoma, BLT1 mediated CD8+ T cell infiltration to tumors is a 
crucial mechanism for effective anti-tumor immunity. Consistent with this 
observation, anti-tumor response in spontaneous ApcMin/+intestinal model of 
tumorigenesis also requires the expression of BLT1 (unpublished data). 
 
Previous studies have reported a pro-tumorigenic role for BLT1-LTB4 pathway, in 
cancer [187, 194-197]. Our studies highlight the importance of BLT1 on immune 
cells (CTLs) in achieving an effective anti-tumor response. Moreover, the data 
presented here suggests that in the absence of BLT1, major CTL chemokine 
receptors like CXCR3 that have been demonstrated to be indispensable for T cell 
trafficking at the tumor vasculature [142], cannot achieve optimum CTL infiltration 
to tumors.  
In a GM-CSF gene transduced leukemia model, Yokota et.al. showed that BLT1-/- 
mice showed similar primary anti-tumor response but enhanced recall memory 
response. The better recall response induced by GM-CSF in BLT1-/- mice was 




enhanced NK cells in the knockout tumors and an enhanced Th1 and 
predominantly skewed Th2 response. In contrast to this crucial finding, our 
results suggest that BLT1-/- mice have a significant defect in primary anti-tumor 
response due to defective CD8+ T cell infiltration in the tumors of BLT1-/- mice; 
the other immune cell subsets remaining similar to those in WT mice. We also 
did not find any difference in the cytotoxic function in BLT1-/- mice as evident 
through in vivo-killing assay by immunization using peptide as well as tumor cells 
(data not shown). The divergence in the results observed can be accounted to 
the differences in the mouse strains (BALB/c) and induction of GM-CSF in the 
tumor cells [187]. GM-CSF is long known to induce DC maturation and T helper 
responses [198]. Also, the BALB/c mice model has been reported to be biased 
towards Th2 response [199] and Th2 responses are crucial for memory anti-
tumor responses [200]. Although we did not find any difference in the numbers of 
CD4+ T cells, NK cells or myeloid cells in the tumors of BLT1-/- mice, the helper 
contributions of CD4+ T cells and NK cells in CD8+ T cell mediated anti-tumor 
immunity cannot be ruled out. Further studies are essential to determine the role 
of LTB4-BLT1 pathway in CD4
+ T cell dependent primary and memory anti-tumor 
responses. 
The role of CXCR3 and the ligands CXCL9 and CXCL10 in anti-tumor immunity 
is well established [81, 142, 143, 201]. In a recent study, Mikuchi et.al elegantly 
demonstrated that CXCR3 mediated signalling to be a critical and an 
indispensable checkpoint for tumor antigen specific CD8+ T cells to traffic across 




human melanoma [142]. CTL chemokine receptors CCR5 and CCR2 were not 
essential for CXCR3 mediated CTL extravasation across tumor vessels despite 
the presence of CCL2 and CCL5 chemokines in the tumor mileu. Using an 
antigen specific B16Ova - OT-I system and ACT setting, they showed that WT 
OT-I but not CXCR3-/- OT-I CTLs were able to significantly reduce tumors; with 
50% of WT OT-I transferred mice showing complete tumor regression. 
Consistent with their study, our data from tumor kinetics in WT versus CXCR3-/- 
mice and adoptive transfer of tumor educated WT or CXCR3 -/- CTLs 
demonstrated a crucial indispensable role for CXCR3 in mediating CTL 
recruitment to tumors and endogenous anti-tumor immunity.  Moreover, in a 
therapeutic vaccine model based on PD-1 blockade in WT or CXCR3-/- tumor 
bearing mice suggested an obligate role for CXCR3 in the success of immune 
checkpoint blockade based therapies. Additionally, we demonstrated an equally 
indispensable role for BLT1 for endogenous anti-tumor immunity and therapeutic 
efficacy. Mikucki et. al. demonstrated an essential role for CXCR3 in mediating 
firm adhesion of tumor Ag specific CD8+ T cells at the tumor vessels while not 
affecting the rolling property of the CTLs. However, at what juncture of the multi-
step trafficking process is BLT1 on CD8+ T cells required for homing into tumors, 
remains to be determined.  
With respect to the functionality of the CD8+ T cells in the tumor 
microenvironment, CXCR3 expression plays a crucial role in interferon gamma 
secretion as CXCR3-/- CTLs in the tumors have a defect in interferon gamma 




of CXCR3-/- T cells [89, 202, 203]. Perturbed amplification loop in IFNγ 
production due to reduced Th1 and NK cells in CXCR3-/- or increased 
suppressive function of M2 macrophages in CXCR3-/- mice may be the reasons 
for defective IFNγ production in CXCR3-/- CD8+ T cells [92, 204]. Another 
explanation of perturbed IFNγ in CXCR3-/- CTLs in tumor microenvironment may 
be due to significantly reduced CD4+ T cells, NK cells and IL-2 (data not shown) 
in those tumors. CD4+ T cells support CD8+ T cell responses not only by IL-2, 
production which is required for survival and expansion of effector T cells but 
also by licensing of APCs [205]. NK cells are also a crucial part of anti-tumor 
immunity. NK cells by secreting IL-2, IFNγ, CXCL10 aids in the maintenance of 
T-helper and CTL population [206]. It is also conceivable that due to less IL-2 
production in the tumors, the survival and effector functions of the CXCR3-/- CTLs 
cells is affected. Importantly, CXCR3 is a major player in the recruitment of T 
cells and NK cells and their survival and effector functions in the tumors. A recent 
study demonstrated that adenosine in the tumor milieu suppressed the 
production of CXCL10 followed by suppression in T cell infiltration; and partial 
reversion was seen upon adenosine receptor blockade [143]. Another study 
suggested that adenosine receptor blockade therapy failed to reduce tumor 
growth in CXCR3-/- mice [207]. Hence, expression of CXCR3 on CTLs in the 
tumor seems crucial for CTL effector function. Also, it is essential to understand 
the roles of BLT1 and CXCR3 on CD4+ T cells and NK cells as well as their 




In general various leukocyte subtypes express several chemo-attractant 
receptors in overlapping patterns (eg. BLT1 is expressed on both activated T 
cells and myeloid cells) and one cell-type express various receptors that can 
respond to multiple chemo-attractant cues that may be present at the target 
tissue. Using a simplified 2D agarose based system where neutrophils 
encountered two different chemoattractant signals in a defined spatial array, 
neutrophils were shown to chemotax sequentially, first migrating up a primary 
gradient of IL-8 into a disorienting concentration which later could effectively 
retain capacity to resume migration to a secondary distant chemoattractant 
gradient of LTB4, suggesting a potential for step-by-step navigation of immune 
cells from one chemo-attractant gradient to another in complex chemo-attractant 
fields [195]. Hence, two attractant pathways specific for the same cell may 
function together rather than being redundant in order to effectively recruit 
immune cells. Our studies suggest that BLT1 and CXCR3 seem to play an 
essential, non-redundant, cell-autonomous role in CD8+ T cell infiltration to 
tumors and anti-tumor immunity.  
We attempted to study the combinatorial regulation of CTL infiltration to tumors 
by BLT1 and CXCR3 via generation of BLT1/CXCR3 double knockout mice 
(DKO). The data presented here suggest a lack of synergism in BLT1 and 
CXCR3 but a probable occurrence of interdependence since there was no further 
enhancement of tumor growth in the DKO mice compared to either of the single 
knockout mice. Studies with the model of arthritis revealed that BLT1 mediated 




BLT1-/- neutrophils to the inflamed joint suggesting that BLT1 expression on 
neutrophils is essential only for the initial recruitment and other chemokines could 
then perpetuate the disease progression [180]. However, our co-transfer 
experiments with WT and individual knockout CTLs revealed that WT CTLs do 
not facilitate additional BLT1-/- or CXCR3-/- CTL infiltration to tumors suggesting 
that BLT1 and CXCR3 mediated signalling cannot be bypassed by other 
chemoattractant systems for CTL migration in to tumors. 
The magnitude of importance of BLT1 and CXCR3 signalling pathways in 
vaccine-induced immune response was tested using immune-checkpoint 
blockade based vaccine. Blockade of Programmed cell Death-1 (PD-1) pathway 
has been recently FDA approved and is a promising anti-tumor immunotherapy 
in humans as it releases the brakes on the T cells thereby enhancing their 
function [208-211]. Anti-PD-1 antibody therapy was shown to enhance T cell 
infiltration of adoptively transferred T cells [211]. The data presented herein 
shows that while anti-PD-1 based vaccine enhanced T cell infiltration to tumors 
thereby reducing tumor growth in WT mice; the vaccine lost its efficacy in the 
absence of either or both BLT1 and CXCR3 receptors, a phenotype ascribed to 
the failure of the knockout CTLs to infiltrate the tumors. We hereby show an 
obligate role for both BLT1 and CXCR3 expression on CTLs in achieving 
optimum anti-PD-1 based vaccine efficacy.  
In lung metastatic melanoma model, melanoma cells were shown to be a source 
for CXCL9 and CXCL10 production. Among the immune cells, CD4+ T cells were 




nodules in lung [143]. While most myeloid cells can readily make LTB4, the 
source of this BLT1 ligand in the B16 tumors remain to be determined.  
 
Taken together, these findings suggest potential ways to improve the current 
ACT therapies, including Chimeric Antigen Receptor (CAR) based therapies by 
employing BLT1 as well as CXCR3 receptor up-regulation strategies on tumor Ag 
specific CD8+ T cells or receptor specific agonists to facilitate increased CTL 
trafficking into tumors. Since studies show that the cells used for ACT already 
have considerable CXCR3 expression on them [142], BLT1 can be upregulated 
on these cells to achieve better infiltration. Alternatively enhancing the CXCR3 
chemokine levels as well as LTB4 levels in the tumor may help achieve increased 
CTL infiltration to tumors. These findings also have an important implication in 
probing the potential efficacy of PD-1 blockade based treatment in patients 
bearing CXCR3 receptor polymorphisms (for e.g. CXCR3rs2280964), which 
results in an altered receptor that fails to be expressed on cell surface [212]. 
Taken together, our studies suggest that, in melanoma tumor, LTB4-BLT1 
pathway, is equally essential as CXCL9/CXCL10 - CXCR3 for CTL migration to 










Immunotherapies have revolutionized the field of cancer therapy and have shown 
considerable efficacy in the clinic. However, the efficacy of the current 
immunotherapy is restricted to a few patients while many patients remain 
unresponsive to treatment. A major obstacle recognized only recently in the 
success of these immunotherapies is defective CD8+ T cell recruitment to tumors 
which significantly impairs the anti-tumor response. Chemokine-chemokine 
receptor signaling is a crucial T cell homing mechanism. Herein, we investigated 
the role of leukotriene B4 receptor BLT1 and CXCL9 and CXCL10 receptor 
CXCR3 in regulating CD8+ T cell migration and anti-tumor immunity using an 
autologous B16 melanoma model. 
The results in this thesis suggest an important role for chemoattractant receptors 
BLT1 and CXCR3 in anti-tumor immune regulation (Figure 29). Both BLT1-/- and 
CXCR3-/- mice demonstrated significantly enhanced tumor growth to a similar 
extent that reduced survival compared to WT mice (Figure 9). Investigating 
cellular mechanisms to this phenotype revealed that BLT1 and CXCR3 both are 
essential for CD8+ T cell migration to tumors, myeloid cell infiltration levels 
remaining similar (Figure 10). Analysis of the effector functions of WT and 
knockout CD8+ T cells revealed no intrinsic defect in killing ability, IFNγ and 
TNFα secretion in the periphery (Figures 15 and 6). However, compared to WT 
CTLs from tumors, CXCR3 deficient CTLs had a significant defect in IFNγ levels 
(Figure 16). This suggests that CXCR3 but not BLT1 signaling is essential in the 




data demonstrated that tumor educated WT but not BLT1 and CXCR3 deficient 
CD8+ T cells reduced tumor growth significantly in Rag2-/- mice. In fact the control 
Rag2-/- mice without any transferred CTLs had similar tumor growth kinetics as 
mice transferred with either of the knockout CTLs. The tumor growth in mice that 
received BLT1 and CXCR3 deficient cells correlated with defective tumoral but 
not TdLN CD8+ T cell infiltration. This reinforced the importance of both BLT1 
and CXCR3 receptor signaling in T cell recruitment into tumors (Figure17 and 
18).   
Analysis of tumor growth in BLT1-CXCR3 double knockout mice suggested 
similar tumor kinetics between BLT1-/-, CXCR3-/- and BLT1-/-CXCR3-/- mice 
indicating a lack of synergism in regulation of anti-tumor immunity (Figure 21). 
The possible inter-dependence was determined by co-transfer of WT with either 
of the knockout CD8+ T cells in tumor bearing Rag2-/- mice. The results obtained 
suggested that WT CTLs did not facilitate additional BLT1-/-, CXCR3-/- or BLT1-/-
CXCR3-/- CTLs into tumors (Figure 24).  
We next sought to investigate the immunotherapy induced responses in BLT1-/-, 
CXCR3-/- and BLT1-/-CXCR3-/- mice. Interestingly, PD-1 blockade based vaccine 
efficacy was completely abolished in the absence of BLT1 and CXCR3 signaling. 
TIL analysis of vaccinated and unvaccinated controls suggested that the vaccine 
enhanced CD8+ T cell infiltration into tumors significantly in WT mice but not the 
knockout mice. The results presented here suggest that BLT1 and CXCR3 




requirement for both BLT1 and CXCR3 in mediating successful checkpoint 
blockade based vaccine efficacy. 
Taken together, the data presented in this thesis suggest an equally crucial role 
for both BLT1 and CXCR3 receptors for efficient CD8+ T cell trafficking to tumors 
and regulation of endogenous as well as immune checkpoint blockade based 
vaccine response. The data obtained from tumor growth in double knockout mice 
and co-transfer experiments indicated that BLT1 and CXCR3 probably are 
components of a single pathway involved in T cell homing processes. Therefore, 
ablation of any one of the receptors or both the receptors has similar end result 
and deficiency in BLT1 is not compensated by CXCR3, making both the genes 













Figure 29: A model for BLT1 and CXCR3 mediated regulation of anti-tumor 
immunity. DCs phagocytose the tumor cells, undergo maturation and migrate to 
the tumor draining lymph nodes where they present the tumor antigen to the T 
cells. The T cells specific for the antigen get activated. Through BLT1 and 
CXCR3, the activated CD8+ T cells then migrate to tumors in response to LTB4 
and CXCL9/10 in tumor microenvironment. The present study suggests that 
BLT1 and CXCR3 are equally important for CTL migration to tumors and anti-
tumor immunity. PD-1 blockade immunotherapy also requires the presence of 
BLT1 and CXCR3 that gives a “T cell inflamed” phenotype in tumor. In the 
absence of BLT1 and CXCR3, the PD-1 blockade therapy completely fails and 




IMPLICATIONS AND FUTURE DIRECTIONS 
The data presented in this thesis suggest an equally crucial role for both BLT1 
and CXCR3 in mediating efficient CD8+ T cell migration to melanoma tumors and 
achieving effective anti-tumor immunity. We demonstrate an important role for 
LTB4-BLT1 axis in mediating immune surveillance in both viral Ag derived TC-1 
cervical cancer as well as autologous B16 melanoma model, suggesting that 
BLT1 mediated CTL recruitment to tumors is true probably across various other 
solid tumors.  
Anti-PD-1 antagonistic antibodies, Nivolumab and Pembrolizumab were recently 
approved by the FDA for treating inoperable end stage melanoma and non-small 
cell lung carcinoma and have shown promising results in the clinic. Our study has 
contributed in the understanding of the factors required for the successful 
efficacy of these therapies. Recent studies have shown that a cohort of patients 
remain unresponsive to this treatment and that the treatment works best in T cell 
inflamed tumor (presence of T cells and T cell chemokines) versus non-T cell 
inflamed tumor (absence of T cells and T cell chemokines). These findings also 
have an important implication in probing the potential efficacy of PD-1 blockade 
and possibly even CTLA4 blockade in patients bearing CXCR3 receptor 
polymorphisms (for e.g. CXCR3rs2280964), which results in an altered receptor 
that fails to be expressed on cell surface. Also, with respect to BLT1 pathway, it 
would be crucial to understand if certain patient specific polymorphisms in BLT1 




and LTA4 hydrolase are associated with unresponsiveness to PD-1 therapies or 
associated with non-T cell inflamed tumors. 
How to redirect the peripheral tumor antigen specific T cells into tumors by 
targeting chemoattractant-chemoattractant receptor interactions is an important 
question requiring research in the area.  Improving CTL recruitment to tumors by 
enhancing LTB4, CXCL9 and CXCL10 ligand levels can potentiate the anti-tumor 
responses. Alternatively, our study has potential implications in improvement of 
CAR-based ACT approaches. Antigen specific chimeric antigen receptors with 
BLT1 or CXCR3 could be designed to improve tumor infiltration of the transferred 
cells and probably reduce toxicities associated with off-target effects of CAR 
therapies. 
It was recently demonstrated by Mikuchi. et.al using intra-vital microscopy that 
CXCR3 is crucial for enabling adhesion and extravasation of antigen specific T 
cells through the tumor endothelium. At what juncture is BLT1 required in this 
process could be answered. 
Future directions of this project could be aimed at understanding the specific cell 
types involved in BLT1 and CXCR3 production in tumors. We currently believe 
that myeloid cells including macrophages and mast cells are the major producers 
of LTB4 at the sites of inflammation. Investigating the same in the context of 
tumors would be important.  
While it is well demonstrated in various studies that immunotherapy including 




CXCL10 in the tumors to aid additional effector cells to migrate in response to the 
increased chemokine gradient in tumors, it would be interesting to understand 
whether PD-1 blockade therapy in melanoma patients induces LTB4 production 
in tumor biopsies. This would add a new mechanism in PD-1 blockade mediated 
chemoattractant induction in the tumor. 
We demonstrated that Anti-PD-1 based vaccine completely lost its efficacy in 
BLT1-/- and CXCR3-/- mice. The question still remains whether defective CTL 
migration is the only cause for the loss in efficacy of the vaccine in knockout 
mice. Possible future experiments must be directed to understand whether tumor 
mutation based neo-antigen-specific T cells in WT versus knockout tumors is 
different. The hypothesis here is that in the absence of CXCR3 and BLT1 
receptors, clonal diversity of neo-antigen specific T cells would be diminished. 
TCR-repertoire sequencing in tumor versus periphery of WT as well as BLT1-/- 
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LIST OF ABBREVIATIONS 
    ABBREVIATION  STANDS FOR  
1. ACT    Adoptive cell therapy 
2. AOM-DSS  Azoxymethane – Dextran sulfate sodium 
3. CAR   Chimeric Antigen Receptor  
4. CTL   Cytotoxic T lymphocyte or CD8+ T cells 
5. CTLA4   Cytotoxic T lymphocyte associate protein 4 
6. COX2   Cyclooxygenase 2 
7. DC   Dendritic Cells 
8. DKO   Double Knockout mice 
9. ECM   Extra cellular matrix 
10.  IL        Interleukin 





12.  IFNγ   Interferon gamma 
13.  IDO   Indoleamine-2,3-dioxygenase 
14.  LTB4   Leukotriene B4 
15.  MDSC   Myeloid Derived Suppressor Cells 
16.  MHC   Major histocompatibility complex  
17.  MSI   Microsatellite Instable 
18.  NSAIDs   Non-steroidal anti-inflammatory drugs 
19.  NK   Natural Killer 
20.  NF-κβ    Nuclear Factor kappa beta 
21. PD-1   Programmed cell Death – 1 
22. PD-L1   Programmed cell Death Ligand - 1 
23. PD-L2   Programmed cell Death Ligand – 2 
24.  Rag2   Recombination activating gene 2 
25.  ROS   Reactive oxygen species 
26.  RNI   Reactive nitrogen intermediates 
27.  STAT   Signal Transducer and Activator of transcription 




29.  TdLN   Tumor draining Lymph Node 
30.  Trp2   Tyrosinase related protein-2 
31.  TIL   Tumor infiltrating leukocytes 
32.  TNFα   Tumor Necrosis Factor alpha 
33.  Treg   Regulatory T cells 
34.  Th    T-helper 
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